<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Neurodegener</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Neurodegener</journal-id>
<journal-title-group>
<journal-title>Molecular Neurodegeneration</journal-title>
</journal-title-group>
<issn pub-type="epub">1750-1326</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31464647</article-id>
<article-id pub-id-type="pmc">6716912</article-id>
<article-id pub-id-type="publisher-id">336</article-id>
<article-id pub-id-type="doi">10.1186/s13024-019-0336-2</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Glucocerebrosidase and its relevance to Parkinson disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Do</surname>
<given-names>Jenny</given-names>
</name>
<address>
<email>jenny.do@nih.gov</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>McKinney</surname>
<given-names>Cindy</given-names>
</name>
<address>
<email>cindy.mckinney@nih.gov</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sharma</surname>
<given-names>Pankaj</given-names>
</name>
<address>
<email>pankaj.sharma2@nih.gov</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Sidransky</surname>
<given-names>Ellen</given-names>
</name>
<address>
<phone>301-451-0901</phone>
<email>sidranse@mail.nih.gov</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2233 9230</institution-id><institution-id institution-id-type="GRID">grid.280128.1</institution-id><institution>Section on Molecular Neurogenetics, Medical Genetics Branch, </institution><institution>National Human Genome Research Institute, National Institutes of Health, </institution></institution-wrap>Building 35A, Room 1E623, 35 Convent Drive, MSC 3708, Bethesda, MD 20892-3708 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>29</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>29</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>14</volume>
<elocation-id>36</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>8</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Mutations in <italic>GBA1</italic>, the gene encoding the lysosomal enzyme glucocerebrosidase, are among the most common known genetic risk factors for the development of Parkinson disease and related synucleinopathies. A great deal is known about <italic>GBA1</italic>, as mutations in <italic>GBA1</italic> are causal for the rare autosomal storage disorder Gaucher disease. Over the past decades, significant progress has been made in understanding the genetics and cell biology of glucocerebrosidase. A least 495 different mutations, found throughout the 11 exons of the gene are reported, including both common and rare variants. Mutations in <italic>GBA1</italic> may lead to degradation of the protein, disruptions in lysosomal targeting and diminished performance of the enzyme in the lysosome.</p>
<p id="Par2">Gaucher disease is phenotypically diverse and has both neuronopathic and non-neuronopathic forms. Both patients with Gaucher disease and heterozygous carriers are at increased risk of developing Parkinson disease and Dementia with Lewy Bodies, although our understanding of the mechanism for this association remains incomplete. There appears to be an inverse relationship between glucocerebrosidase and α-synuclein levels, and even patients with sporadic Parkinson disease have decreased glucocerebrosidase. Glucocerebrosidase may interact with α-synuclein to maintain basic cellular functions, or impaired glucocerebrosidase could contribute to Parkinson pathogenesis by disrupting lysosomal homeostasis, enhancing endoplasmic reticulum stress or contributing to mitochondrial impairment. However, the majority of patients with <italic>GBA1</italic> mutations never develop parkinsonism, so clearly other risk factors play a role. Treatments for Gaucher disease have been developed that increase visceral glucocerebrosidase levels and decrease lipid storage, although they have yet to properly address the neurological defects associated with impaired glucocerebrosidase. Mouse and induced pluripotent stem cell derived models have improved our understanding of glucocerebrosidase function and the consequences of its deficiency. These models have been used to test novel therapies including chaperone proteins, histone deacetylase inhibitors, and gene therapy approaches that enhance glucocerebrosidase levels and could prove efficacious in the treatment of forms of parkinsonism. Consequently, this rare monogenic disorder, Gaucher disease, provides unique insights directly applicable to our understanding and treatment of Parkinson disease, a common and complex neurodegenerative disorder.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Gaucher disease</kwd>
<kwd>
<italic>GBA1</italic>
</kwd>
<kwd>Parkinson disease</kwd>
<kwd>Glucocerebrosidase</kwd>
<kwd>α-Synuclein</kwd>
<kwd>Lysosome</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000051</institution-id>
<institution>National Human Genome Research Institute</institution>
</institution-wrap>
</funding-source>
<award-id>Intramural Research Program</award-id>
<principal-award-recipient>
<name>
<surname>Sidransky</surname>
<given-names>Ellen</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par37">Of all the known genetic variants associated with Parkinson disease, mutations in <italic>GBA1</italic>, the gene encoding the lysosomal enzyme glucocerebrosidase (Glucosylceramidase Beta or GCase; EC 3.2.1.45), have a major advantage due to the association of this gene with a well-studied lysosomal storage disorder, Gaucher disease. Gaucher disease, an autosomal recessively inherited disorder with diverse clinical manifestations, was first described in Paris over 135 years ago by a medical student, Philippe Gaucher, who examined a patient with a massively enlarged spleen [<xref ref-type="bibr" rid="CR1">1</xref>]. It was not until a half century later that it was discovered that the stored material found in patients with this disorder was in fact a glycolipid, glucosylceramide (GlcCer) [<xref ref-type="bibr" rid="CR2">2</xref>]. In 1965, Dr. Roscoe Brady at the National Institutes of Health in Bethesda, Maryland determined that Gaucher disease resulted from an enzymatic defect in the lysosomal enzyme glucocerebrosidase (GCase), that normally cleaves a glucose moiety from GlcCer [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. This finding facilitated purification of the protein GCase, the cloning of the <italic>GBA1</italic> gene in 1981, and the development of enzyme replacement therapy (ERT) as a treatment for patients with Gaucher disease [<xref ref-type="bibr" rid="CR4">4</xref>]. Indeed, much work in the past decades has focused on mutations in <italic>GBA1</italic> and their phenotypic consequences. Thus, unlike other newly discovered Parkinson genes, a great deal is known about <italic>GBA1</italic> and the function of its resulting enzyme, GCase.</p>
<sec id="Sec2">
<title>Glucocerebrosidase: biochemistry and molecular biology</title>
<p id="Par38">GCase is a 497-amino-acid membrane-associated protein with a 39-amino-acid leader sequence and five glycosylation sites [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The protein is synthesized in the endoplasmic reticulum (ER) and glycosylated, but the enzyme only becomes active when transferred to the acidic lumen of the lysosome (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). Unlike other lysosomal proteins that are targeted to the lysosome by mannose-6-phosphate receptor dependent pathways, GCase is transported from the ER by the GCase transporter lysosomal integral membrane protein-2 (LIMP2), encoded by the gene <italic>SCARB2</italic> [<xref ref-type="bibr" rid="CR6">6</xref>]. Once in the lysosome, the enzyme interacts with another partner, its activator protein saposin C (SAPC) [<xref ref-type="bibr" rid="CR7">7</xref>], a subunit of the precursor protein, prosaposin (PSAP). In the lysosomal compartment, the enzyme hydrolyzes glucose moieties from both GlcCer and glucosylsphingosine (GlcSph) (Fig. <xref ref-type="fig" rid="Fig2">2</xref>).
<fig id="Fig1"><label>Fig. 1</label><caption><p>Simplified diagram of the synthesis and trafficking of GCase in a functional cell. 1) <italic>GBA1</italic>, the gene coding for GCase, is transcribed into mRNA that is then transported out of the nucleus to the ER. 2) GCase is synthesized in the ER, where it binds to the protein LIMP2 in the favorable neutral pH of the cytoplasm. 3) LIMP2 transfers GCase through the Golgi. 4) GCase is then transferred to a late endosome. 5) When the late endosome fuses with a lysosome to form an autolysosome, LIMP2 disengages from GCase due to the decrease in pH. In the lysosome, GCase is activated by SAPC. GCase actively hydrolyzes its substrates GlcCer and GlcSph in this compartment</p></caption><graphic id="MO1" xlink:href="13024_2019_336_Fig1_HTML"></graphic></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Reaction schema depicting the enzyme GCase hydrolyzing GlcCer and GlcSph. In the lysosome, GCase hydrolyzes substrates GlcCer (above) and GlcSph (below) by cleaving a glucose moiety off the molecule, creating the products glucose and ceramide, or glucose and sphingosine, respectively</p></caption><graphic id="MO2" xlink:href="13024_2019_336_Fig2_HTML"></graphic></fig></p>
<p id="Par39">The <italic>GBA1</italic> gene is located in a gene-rich region on chromosome 1q21. It is composed of 11 exons and includes around 7000 base pairs of DNA [<xref ref-type="bibr" rid="CR8">8</xref>]. A highly homogenous, untranslated pseudogene that shares 98% homology in the coding regions is located only 16 kb downstream. A second gene, metaxin 1 (<italic>MTX1</italic>), encoding a protein located in the outer mitochondrial membrane, is located downstream to the <italic>GBA1</italic> pseudogene sequence and is convergently transcribed [<xref ref-type="bibr" rid="CR9">9</xref>]. There is also a <italic>MTX1</italic> pseudogene located in between <italic>GBA1</italic> and its pseudogene. The gene for thrombospondin 3 (<italic>TPS3</italic>), a glycoprotein that mediates cell-to -matrix and cell-cell interactions, is immediately downstream to <italic>MTX1</italic> (Fig. <xref ref-type="fig" rid="Fig3">3</xref>).
<fig id="Fig3"><label>Fig. 3</label><caption><p>Scaled map of a 50 kb gene-rich region surrounding/antecedent to the <italic>GBA1</italic> gene on chromosome 1q21. Genes represented above the line are transcribed right to left, while the genes below are transcribed left to right. Note the close proximity of <italic>GBA1</italic> to its pseudogene with 98% homology, making it a common site for recombination events [<xref ref-type="bibr" rid="CR9">9</xref>]</p></caption><graphic id="MO3" xlink:href="13024_2019_336_Fig3_HTML"></graphic></fig></p>
<p id="Par40">At least 495 known <italic>GBA1</italic> mutations are associated with Gaucher disease, the majority being missense mutations [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Mutation nomenclature is complicated, as the numbering of the mutated amino acid was changed several years ago to include the 39-amino-acid leader sequence (newer numbering shown in parentheses). There are two common mutations found in patients. The mutation N370S (p.N409S), found exclusively in patients with type 1 Gaucher disease, is the most frequent mutation encountered among patients in the United States, Europe and Israel. The L444P (p.L483P) mutation is found world-wide, and when homozygous, is frequently associated with neuronopathic Gaucher disease. Other identified mutations, located across all exons of <italic>GBA1</italic>, include point mutations, frame shifts, splicing mutations, and null alleles often resulting from recombination with the homologous pseudogene sequence [<xref ref-type="bibr" rid="CR12">12</xref>]. Many <italic>GBA1</italic> mutations are relatively common, but others are rarer, found only in individual families.</p>
</sec>
<sec id="Sec3">
<title>Gaucher disease</title>
<p id="Par41">Overall, Gaucher disease is a pan-ethnic disorder affecting between 1 in 50,000 to 1 in 100,000 people world-wide [<xref ref-type="bibr" rid="CR4">4</xref>]. The frequency of Gaucher disease is increased in the Ashkenazi Jewish population where the carrier frequency is between 1 in 14 to 1 in 18. Screening for 6–8 specific <italic>GBA1</italic> mutations can identify around 95% of mutant alleles in Ashkenazi Jewish patients with Gaucher disease, while the genotypic diversity is far broader in other ethnicities.</p>
<p id="Par42">Gaucher disease results from the deficiency of lysosomal GCase and the accumulation of the lipid substrates GlcCer and GlcSph within the lysosomes of macrophages. These engorged cells are referred to as “Gaucher cells” and have a unique “crumpled tissue paper-like” appearance on hematoxylin and eosin staining. Electron microscopy of Gaucher macrophages show inclusions with a tubular structure [<xref ref-type="bibr" rid="CR13">13</xref>]. These distinctive cells are commonly found in the spleen, liver, lung and bone marrow, leading to symptoms in these specific organs. Painless splenomegaly is often the first sign of Gaucher disease and is sometimes accompanied by hepatomegaly. Thrombocytopenia and anemia are also quite common. Bone disease, including painful bone “crises”, as well as fractures and osteopenia, are significant causes of morbidity in patients.</p>
<p id="Par43">By definition, patients who have no neurological involvement as a result of their GCase deficiency are considered to have type 1 or non-neuronopathic Gaucher disease. Among patients with type 1 Gaucher disease, symptoms are highly variable, and the disease can present at any age. Phenotypes include children with cytopenia and organomegaly, adolescents with bone pain and fractures requiring orthopedic surgery, and asymptomatic older adults. While numerous mutations have been identified in patients with type 1 Gaucher disease, mutation N370S is the mutation most commonly encountered, and homozygosity for N370S is often seen among the patients with the mildest phenotypes. However, genotype-phenotype associations have limited value, as even some patients with genotype N370S/N370S develop serious disease complications [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
<p id="Par44">Brain involvement resulting from GCase deficiency can also occur, and the associated manifestations are quite diverse. Acute neuronopathic or type 2 Gaucher disease presents perinatally or in the first months of life [<xref ref-type="bibr" rid="CR15">15</xref>]. It is a devastating disorder accompanied with neurodegeneration and brainstem involvement. Infants have organomegaly, failure-to-thrive, and compromised swallow and airway problems. Associated genotypes include homozygosity for a recombinant allele, frame-shift mutation, or other severe mutations. Compound heteroallelic genotypes comprised of functionally “null” mutations together with a L444P allele are also associated with type 2 Gaucher disease [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
<p id="Par45">Patients with any neurologic involvement who do not fit into the category of type 2 Gaucher disease are considered to have type 3 Gaucher disease, which is a very phenotypically diverse group. The most common and perhaps defining manifestation encountered in patients with type 3 Gaucher disease is the slowing or looping of the horizontal saccadic eye movements. Other features described include myoclonic epilepsy, generalized seizures, and learning and behavioral difficulties. However, in some patients, the eye movement findings are the sole neurologic manifestation [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
<p id="Par46">Non-neuronopathic Gaucher disease and the visceral manifestations of type 3 Gaucher disease can be effectively treated. Enzyme replacement therapy (ERT), available since 1991, consists of biweekly intravenous infusions of recombinant GCase [<xref ref-type="bibr" rid="CR18">18</xref>]. Substrate reduction therapy (SRT), an oral drug inhibiting the synthesis of GlcCer, is available for adults with Gaucher disease and is also shown to reverse visceral disease manifestations [<xref ref-type="bibr" rid="CR19">19</xref>]. Nevertheless, ERT and SRT therapies are extremely costly; moreover, ERT does not cross the blood-brain-barrier, and is therefore unable to prevent neurodegeneration. While the most widely used SRT is not brain penetrant, others that can cross the blood-brain barrier are undergoing clinical trials [<xref ref-type="bibr" rid="CR20">20</xref>]. Alternate strategies, including small molecule chaperones and gene therapy, are being explored and developed.</p>
</sec>
<sec id="Sec4">
<title><italic>GBA1</italic> and parkinsonism</title>
<p id="Par47">The association between mutations in <italic>GBA1</italic> and the development of parkinsonism was first appreciated in the 1990’s with the identification of rare patients with Gaucher disease who also developed Parkinson disease [<xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR23">23</xref>]. It was subsequently appreciated that Parkinson disease was more common in heterozygote family members of patients with Gaucher disease [<xref ref-type="bibr" rid="CR24">24</xref>]. Pilot studies conducted with brain bank samples [<xref ref-type="bibr" rid="CR25">25</xref>], and in Parkinson disease clinics, suggested that patients with Parkinson disease sometimes carried <italic>GBA1</italic> mutations [<xref ref-type="bibr" rid="CR26">26</xref>]. Ultimately, studies in large Parkinson disease cohorts and a multicenter international collaborative study established that in Parkinson disease world-wide, the odds ratio for a mutation in <italic>GBA1</italic> was greater than five [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Today it is estimated that between 7 and 12% of patients with Parkinson disease carry a <italic>GBA1</italic> mutation. The frequency varies depending on the population; for example, since the carrier frequency of <italic>GBA1</italic> mutations is much higher among Ashkenazi Jews, over 15% of Ashkenazi Jewish patients with Parkinson disease carry at least one common <italic>GBA1</italic> mutation [<xref ref-type="bibr" rid="CR27">27</xref>]. There is some indication that mutant alleles associated with more severe Gaucher disease have a higher associated risk of developing parkinsonism [<xref ref-type="bibr" rid="CR29">29</xref>].</p>
<p id="Par48">Despite the increased risk of developing parkinsonism among <italic>GBA1</italic> mutation carriers, it is important to emphasize that only a minority of carriers with <italic>GBA1</italic> mutations ever develop Parkinson disease. The same applies even to patients with Gaucher disease, despite exhibiting significantly attenuated GCase activity as a result of two mutated <italic>GBA1</italic> alleles [<xref ref-type="bibr" rid="CR30">30</xref>]. A study from 2011 reports that in a registry of 4051 adult patients with type 1 Gaucher disease, 68 were diagnosed with Parkinson disease [<xref ref-type="bibr" rid="CR31">31</xref>]. After age-matching, the probability of patients developing Parkinson disease was calculated as 5–7% by age 70 and 9–12% by age 80. However, these results are limited by the nature of the study design and the information available in the International Collaborative Gaucher Group (ICGG) registry, as not all Gaucher patients are registered in the ICGG, especially in cases where patients’ symptoms are so mild that their Parkinson diagnosis precedes their Gaucher diagnosis [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Additionally, the registry does not include carriers of just one <italic>GBA1</italic> mutation. As a result, the incidence of Parkinson disease in patients with Gaucher disease remains difficult to quantify. However, one study noted that although the incidence of Parkinson disease is similar in homozygote and heterozygote carriers of <italic>GBA1</italic> mutations, the age of onset for homozygotes are approximately 6–11 years earlier than in heterozygotes [<xref ref-type="bibr" rid="CR34">34</xref>]. Furthermore, the connection between GCase activity and Parkinson disease is complicated by the fact that two mild <italic>GBA1</italic> alterations that do not in themselves cause Gaucher disease, E326K (p.E365K) and T369 M (p.T408 M), still predispose patients to parkinsonism [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. While no potential mechanism has been described for these mutations, it is possible that the combined effect of the mutation with assorted environmental or non-<italic>GBA1</italic> genetic factors induce a higher risk for Parkinson disease. This suggests that the factors leading to Parkinson pathogenesis are multifaceted in nature and are not completely explained by deficient lysosomal activity and the accumulation of substrate. Therefore, unlike certain genes leading to familial, monogenic forms of Parkinson disease, <italic>GBA1</italic> mutations should be considered only as a risk factor for parkinsonism.</p>
</sec>
<sec id="Sec5">
<title>The biological role of glucocerebrosidase in Parkinson pathogenesis</title>
<p id="Par49">Since the link between Gaucher heterozygotes and Parkinson disease was established, it is recognized that deficient GCase has some biological role as a modifier or facilitator of Parkinson pathogenesis in the brain. In fact, brain autopsy studies have shown that even some cases of idiopathic Parkinson disease (without <italic>GBA1</italic> mutations) exhibit decreased levels of GCase [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p>
<p id="Par50">As mentioned, after synthesis in the ER, wildtype GCase hydrolyzes glucose from GlcCer and GlcSph in the lysosomal lumen. Once thought to be the cellular endpoint of endocytosis and removal of cellular debris, the lysosome is now recognized as a vital and interconnected organelle. It monitors nutrient status, it actively communicates with the nucleus via a master regulator, Transcription Factor EB (TFEB), it acts as a secretory center for some macromolecules, and it contains more than 60 acidic hydrolases that degrade macromolecules delivered by the endocytic and autophagic pathways [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Several studies postulate how potential interactions in the autophagic pathway can promote Parkinson pathology, speculating that a reduction in GCase activity may enhance the risk for Parkinson disease by facilitating the pathological hallmark for Parkinson disease, α-synuclein accumulation. Many studies are now addressing how normal levels of GCase protein might interplay with α-synuclein to maintain neurological function [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p>
</sec>
<sec id="Sec6">
<title>The role of α-Synuclein in Parkinson pathogenesis</title>
<p id="Par51">Parkinson disease, characterized by bradykinesia, rigidity, and tremor, is associated with the loss of dopaminergic neurons and by the accumulation of insoluble α-synuclein fibrils in the form of Lewy bodies and neurites in the substantia nigra of the brain. The involvement of α-synuclein in Parkinson disease was elucidated when a missense mutation (p.A53T) was documented in the α-synuclein gene (<italic>SCNA</italic>) in an extended Italian kindred with hereditary Parkinson disease [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. It was further substantiated when α-synuclein was found to be a component of Lewy bodies 1 year later [<xref ref-type="bibr" rid="CR43">43</xref>]. There is some evidence suggesting that α-synuclein is a soluble protein that may exist in the cell primarily as a helical tetramer that is resistant to aggregation, although this remains controversial [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. In the cell, α-synuclein is in equilibrium between a soluble (cytosolic) form and a membrane bound form [<xref ref-type="bibr" rid="CR46">46</xref>]. Its function remains unclear, but is speculated to be involved in exocytosis, and along with its isoforms β- and γ-synuclein, it is expressed in specific brain regions and likely involved in presynaptic neural transmissions to the dendrites of a postsynaptic neuron (reviewed in [<xref ref-type="bibr" rid="CR47">47</xref>]). α-Synuclein requires interacting molecular partners like SNARE proteins, lipid membranes, dopamine homeostatic proteins, calcium regulating proteins, α-synuclein itself and others to function in the cell [<xref ref-type="bibr" rid="CR47">47</xref>]. Under conditions where the local concentration of α-synuclein is high, it can self-assemble to form insoluble α-synuclein aggregates and fibrils. This aggregation process is enhanced by pre-existing aggregates, so α-synuclein can self-seed to increase these insoluble forms, much like misfolded prion proteins. α-Synuclein is cleared from the cells by macroautophagy, a general degradative cell function, and by chaperone mediated autophagy (CMA) requiring lysosome-associated membrane protein 2a (LAMP2a), another lysosomal transporter that mediates entry of molecules to the lysosome [<xref ref-type="bibr" rid="CR48">48</xref>]. Additionally, it was shown that α-synuclein pathology reduces CMA pathway activity at its lysosomal entry receptor [<xref ref-type="bibr" rid="CR49">49</xref>]. It is possible that the conversion of the physiologically active soluble form of α-synuclein to the insoluble aggregate form is one of many factors promoting Parkinson disease and other neurodegenerative synucleinopathies.</p>
</sec>
<sec id="Sec7">
<title>The association between GCase and α-Synuclein</title>
<p id="Par52"><italic>GBA1</italic> mutations may structurally change the GCase protein, resulting in decreased enzymatic activity (loss of function). In theory, these consequences may occur in several ways and postulated hypotheses include: 1) failure of the GCase protein to exit the ER, 2) failure of GCase to link with its trafficking transporter, LIMP2, 3) misfolded and unstable GCase is degraded by the proteasome, 4) failure of GCase to exit the Golgi, 5) GCase is inactive due to mutations at the active site, and 6) GCase activity is altered due to a Saposin C defect. (Fig. <xref ref-type="fig" rid="Fig4">4</xref>).
<fig id="Fig4"><label>Fig. 4</label><caption><p>Different hypothetical mechanisms by which GCase can be impaired, and various therapeutic approaches targeting these mechanisms. These include A) failure of the GCase protein to exit the ER, B) failure of GCase to link with its LIMP2 trafficking transporter, C) GCase is misfolded and unstable, so degraded through the unfolded protein response, D) failure of GCase to exit the Golgi, E) GCase is inactive due to mutations at the active site, and F) GCase activity is altered due to a Saposin C defect, and. The failure of GCase to reach the lysosome or be activated in the lysosome enables GlcCer and GlcSph to accumulate in the lysosome, creating the hallmark marker of Gaucher disease, Gaucher cells. Various therapies to address GCase impairment include: 1) Gene therapy: directly replacing mutant DNA with corrected DNA via adeno-associated or other viral infection. 2) Pharmacological chaperone therapy: introducing chaperone proteins to stabilize and refold misfolded proteins. 3) Histone deacetylase inhibitors: inhibiting unfolded protein response to allow more misfolded proteins to reach the lysosome. 4) Enzyme replacement therapy (ERT): replacing dysfunctional enzyme with recombinant enzyme targeted to the lysosome. 5) Substrate reduction therapy (SRT): reducing substrate accumulation regardless of GCase levels by inhibiting substrate synthesis. Currently, ERT and SRT are the only FDA-approved treatment options for patients with Gaucher disease</p></caption><graphic id="MO4" xlink:href="13024_2019_336_Fig4_HTML"></graphic></fig></p>
<p id="Par53">Regardless of degree of GCase deficiency, patients with <italic>GBA1</italic>-associated Parkinson disease appear to have increased α-synuclein aggregation. Post-mortem analysis of brain tissue from patients with Parkinson disease and those with Gaucher and Parkinson disease [<xref ref-type="bibr" rid="CR50">50</xref>] demonstrated that decreases in GCase in the substantia nigra correlate with increases in α-synuclein levels. Moreover, Mazzulli et al. [<xref ref-type="bibr" rid="CR51">51</xref>] showed that reduced GCase activity in cultured neurons resulted in reduced clearance, and subsequently increased levels, of α-synuclein protein. Decreases in GCase activity in the lysosome are also associated with accumulation of substrates GlcCer and GlcSph, with GlcSph being the more cytotoxic storage product [<xref ref-type="bibr" rid="CR52">52</xref>]. GCase may also cleave galactosylceramide (GalCer) [<xref ref-type="bibr" rid="CR53">53</xref>] to galactose and ceramide, thus loss of GCase activity may lead to GalCer accumulation as well. GCase has a broad enzymatic profile and may also act to transfer a glucose from GlcCer to cholesterol producing glycosylated cholesterol (GlcChol) [<xref ref-type="bibr" rid="CR54">54</xref>]. Consequently, not only do GlcCer and GlcSph increase beyond homeostatic levels, but the accumulation of GlcChol and many other glucose-conjugated lipids may alter the cell’s ability to function. For example, it was recently noted in PD fibroblasts that the <italic>GBA1</italic> mutation N370S mediated lysosomal accumulation of cholesterol, that, in turn, may alter LIMP2 function [<xref ref-type="bibr" rid="CR53">53</xref>]. In addition, accumulated GlcCer substrate was found to directly influence the conformation and solubility of α-synuclein by stabilizing the levels of soluble intermediates [<xref ref-type="bibr" rid="CR51">51</xref>]. However, this association remains controversial because substrate accumulation is not observed in the brains of PD patients with heterozygous <italic>GBA1</italic> mutations [<xref ref-type="bibr" rid="CR20">20</xref>]. It is possible that α-synuclein accumulation in lysosomes may reduce overall GCase activity in lysosomes, further compounding the issue. These findings underscore the complex cascade that can result from the loss of GCase and that may contribute to the generation of α-synuclein aggregates leading to Parkinson pathogenesis.</p>
<p id="Par54">Loss of GCase activity can be acquired in many ways, but it is clear that a variety of factors including loss of GCase function, increased storage of intermediates like GlcCer, decreased transport of GCase from the ER or CMA disruption ultimately lead to increased α-synuclein accumulation, and a change from the soluble form to the aggregate form. The role of GCase in α-synuclein degradation appears to be important to maintaining homeostatic levels of monomeric α-synuclein in the cell, as enhanced GCase activity leads to reduced α-synuclein levels in iPSC-derived dopamineurgic neurons [<xref ref-type="bibr" rid="CR55">55</xref>]. It has therefore been suggested that GCase and α-synuclein may have co-evolved to preserve a synergistic surface interaction around the GCase active site, but, if true, this role has yet to be defined [<xref ref-type="bibr" rid="CR55">55</xref>]. Understanding the physical interactions between GCase and α-synuclein within the lysosomal pathway and the cascading effects on other aspects of Parkinson development may provide common intervention points for therapeutic approaches for both Gaucher and Parkinson disease.</p>
</sec>
<sec id="Sec8">
<title>The protein structure of glucocerebrosidase and α-Synuclein and possible interacting domains</title>
<p id="Par55">The mature GCase protein consists of 497 residues and has a calculated molecular mass ranging between 55 and 69 kDa depending on the number of occupied glycosylation sites. The X-ray crystal structure of GCase was first published in 2003 at a 2.0 Å resolution [<xref ref-type="bibr" rid="CR56">56</xref>]. The protein consists of three domains. Domain I (residues 1–27 and 383–414) is composed of an antiparallel β sheet flanked by an amino terminal strand and a loop. This domain also contains two disulfide bridges (residues 4–16 and 18–23) which are required for correct folding of the protein [<xref ref-type="bibr" rid="CR56">56</xref>]. Domain II (residues 30–75 and 431–497) is an immunoglobulin-like domain comprised of two closely associated β sheets. Domain III contains the catalytic domain (residues 76–381 and 416–430) and is a (β/α)<sub>8</sub> triosephosphate isomerase (TIM) barrel with three free cysteines at residues 126, 248 and 342. Domains II and III appear to be linked by a flexible hinge, while domain I strongly interacts with domain III [<xref ref-type="bibr" rid="CR56">56</xref>]. The common mutation N370S is located in the longest helix in the protein (helix 7) at the interface of domains II and III, but is too far from the active site to participate directly in catalysis. Several other mutations are found in this helix, all of which seem to point into the TIM barrel. Another common Gaucher mutation, L444P, is located in the hydrophobic core of the Ig-like domain (domain II). Any mutation in this domain may produce an unstable protein due to disruption of the hydrophobic core and altered folding of this domain [<xref ref-type="bibr" rid="CR57">57</xref>].</p>
<p id="Par56">There is also data suggesting that GCase can exist as a dimer in vivo<italic>.</italic> While different dimer forms are likely present, it was predicted that the form where the catalytic site is buried at the dimer interface is the preferred structure [<xref ref-type="bibr" rid="CR58">58</xref>]. More recently, transition electron microscopy studies have clearly shown that GCase has a butterfly-shaped dimer structure both in solution and as a crystal, and that the dimer interface provided an allosteric binding pocket that may be significant for the design of future therapeutics [<xref ref-type="bibr" rid="CR58">58</xref>].</p>
<p id="Par57">In contrast to the highly structured GCase, α-synuclein is a small pre-synaptic protein of 140 amino acid with a less rigid structure and a propensity to form aggregates. It consists of three domains including the amino terminal lipid-binding α-helix, an amyloid-binding domain, and a carboxy-terminal acidic tail [<xref ref-type="bibr" rid="CR59">59</xref>]. Using fluorescence and NMR spectroscopy, Yap et al. [<xref ref-type="bibr" rid="CR60">60</xref>] showed that GCase interacts in close proximity with the C terminal of the α-synuclein protein in the acidic environment (pH 5.5) of the lysosome. It was postulated that α-synuclein is docked with GCase in the region of three highly conserved surface histidines (His-223, His-273 and His-328). The interacting C-terminus of α-synuclein (residues 126–140) are situated near loop 1 in the groove between the GCase C-terminus β sheet domain and the TIM barrel. It is suggested that interaction of α-synuclein with wildtype GCase promotes lysosomal degradation of α-synuclein or inhibits excessive α-synuclein accumulation. However, while evidence for the α-synuclein-GCase complex exists in vitro, not much is known regarding the mechanism through which the complex impacts α-synuclein stability or expression levels.</p>
</sec>
<sec id="Sec9">
<title>ER stress, uncoupling of the protein response and autophagy</title>
<p id="Par58">Misfolded proteins accumulating in the ER as a result of <italic>GBA1</italic> mutations can lead to ER stress while also activating the unfolded protein response (UPR). The UPR is upregulated in an attempt to protect the neural cell from the impact of chronic stress [<xref ref-type="bibr" rid="CR61">61</xref>]. Two UPR chaperone mediators, GRP78 and calreticulin, were altered in <italic>GBA1-</italic>N370S dopaminergic neurons when compared to controls [<xref ref-type="bibr" rid="CR62">62</xref>]. In an <italic>A53T</italic> mouse model of synucleinopathy [<xref ref-type="bibr" rid="CR61">61</xref>], levels of the ER chaperone GRP78 were elevated in symptomatic mice [<xref ref-type="bibr" rid="CR14">14</xref>]. It was also reported [<xref ref-type="bibr" rid="CR63">63</xref>] that ER stress in a mouse model originated in the ER lumen/microsome fraction of the cell. In a <italic>Drosophila</italic> model containing a <italic>GBA1</italic> Rec<italic>Nci</italic>1 complex allele, the mutated GCase protein was also found to contribute to ER stress, resulting in alterations in eye development and increases in the ER stress marker, xbp1-EGFP [<xref ref-type="bibr" rid="CR64">64</xref>]. Autophagosome markers (LC3 I and II, Beclin-1) were evaluated in iPSC-derived dopaminergic neurons from patients carrying a N370S allele, and independently in those from patients with a <italic>SCNA</italic> triplication. Both mutated lines showed disruption of the autophagy pathway [<xref ref-type="bibr" rid="CR62">62</xref>] and up-regulation of the UPR [<xref ref-type="bibr" rid="CR65">65</xref>]. The <italic>SCNA</italic> triplication demonstrated that α-synuclein accumulation significantly activates the UPR in a model independent of alterations in GCase activity. Consequently, cellular impairments that alter protein processing by a variety of mechanisms, including trapping of mutant GCase in the ER, can lead to α-synuclein accumulation and further disruption of vesicular trafficking. GlcCer accumulation in the lysosomes can also hinder lysosome-autophagy transport and degradation pathways and lead to increased α-synuclein aggregates [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Conduritol–β-epoxide (CBE), an inhibitor of GCase, was also shown to increase α-synuclein accumulation in midbrain dopaminergic neurons [<xref ref-type="bibr" rid="CR66">66</xref>], indicating that loss of GCase activity from mutant protein and/or increase in GlcCer are sufficient to promote α-synuclein aggregates. It is speculated that early intervention to alleviate ER stress before α-synuclein forms insoluble aggregates and fibrils may be a valuable therapeutic approach, since early aggregate forms can be reversed [<xref ref-type="bibr" rid="CR67">67</xref>].</p>
</sec>
<sec id="Sec10">
<title>Dysfunction of lysosomal trafficking</title>
<p id="Par59">GCase reaches the lysosome by interacting with LIMP2, a protein that facilitates the trafficking of this acid hydrolase to the lysosomal lumen. Consequently, mutations in <italic>SCARB2,</italic> the gene that encodes LIMP2, can also contribute to reduced GCase activity [<xref ref-type="bibr" rid="CR68">68</xref>]. Thus, impaired transport of GCase to the lysosome can contribute to reduced GCase activity even in the absence of GCase mutations. Other studies suggest that increases in α-synuclein disrupt ER to Golgi trafficking of GCase, setting up a bidirectional feedback loop, wherein decreases in GCase activity or increases in GlcCer yield increased levels of α-synuclein, that in turn accentuate α-synuclein aggregation. This is a GCase-specific defect, since leupeptin, a general lysosomal inhibitor, did not promote α-synuclein accumulation [<xref ref-type="bibr" rid="CR68">68</xref>].</p>
</sec>
<sec id="Sec11">
<title>Mitochondrial impairment/oxidative stress</title>
<p id="Par60">There is evidence suggesting that mitochondrial import proteins may interact with α-synuclein via a cryptic mitochondrial import signal [<xref ref-type="bibr" rid="CR69">69</xref>]. Mutations in <italic>PARK2</italic> (Parkin) and <italic>PINK1</italic> (PTEN-induced putative kinase), that result in monogenic Parkinson disease, are believed to impact mitochondrial function by increasing susceptibility to toxins [<xref ref-type="bibr" rid="CR70">70</xref>]. Using a neuronopathic mouse model (K14-lnl/lnl) of Gaucher disease [<xref ref-type="bibr" rid="CR71">71</xref>], Ossellame et al. [<xref ref-type="bibr" rid="CR72">72</xref>] found that autophagic and proteasomal pathways were compromised in both neurons and astrocytes and showed insoluble α-synuclein accumulation in neurons. In this mouse, mitochondria were mis-shaped, fragmented and had reduced respiratory chain activity. In cell studies, reduction of GCase activity resulted in a progressive loss of mitochondria membrane potential required for ATP production, loss of respiratory complex activity, fragmented mitochondria and oxidative stress [<xref ref-type="bibr" rid="CR73">73</xref>]. Finally, calcium regulation may also be affected in damaged mitochondria, yielding an altered membrane potential [<xref ref-type="bibr" rid="CR74">74</xref>]. Mitochondrial dysfunction may also produce reactive oxygen species (ROS), causing chronic oxidative stress that may initiate misfolding of α-synuclein [<xref ref-type="bibr" rid="CR75">75</xref>] and may initiate other degradative pathways in the neuron. Thus, secondary mitochondria dysfunction possibly results from a primary lysosomal defect (loss of GCase activity) that profoundly alters mitochondrial function. Cellular disruptions including ER stress, ROS and mitophagy may further compound the loss of cellular homeostasis and promote α-synuclein aggregation.</p>
</sec>
<sec id="Sec12">
<title>Potential genetic modifiers of <italic>GBA1</italic> function</title>
<p id="Par61">Genes that directly modulate the expression of another gene are known as genetic modifiers. While the association between <italic>GBA1</italic> and Parkinson disease is well-established, genetic modifiers may hold the key to elucidating <italic>GBA1</italic>-associated Parkinson genotype-phenotype correlation and underlying mechanisms of Parkinson pathogenesis. This subject has recently been extensively reviewed [<xref ref-type="bibr" rid="CR76">76</xref>].</p>
<p id="Par62">The search for modifiers began with a focus on candidate genes, but most of these pilot studies were not fruitful. Screening the closely located <italic>MTX1</italic> gene in 600 Ashkenazi Jewish patients with Parkinson and 353 control patients suggested that homozygosity for the <italic>MTX1</italic> c.184 T &gt; A (p.S63 T) alteration induces earlier onset of Parkinson disease in affected patients [<xref ref-type="bibr" rid="CR77">77</xref>]. A GWAS performed in 153 Ashkenazi Jewish patients with <italic>GBA1</italic>-associated Parkinson disease highlighted the gene <italic>BIN1</italic> as a potential candidate modifier gene for early-onset <italic>GBA1</italic>-associated Parkinson disease <italic>BIN1</italic> encodes the Bridging Integrator 1 (BIN1) protein, a protein involved in CNS synaptic vesicle endocytosis [<xref ref-type="bibr" rid="CR78">78</xref>]. Mutations in <italic>BIN1</italic> are thought to induce early-onset Parkinson disease in patients with at least one mutated <italic>GBA1</italic> allele. However, this finding did not reach genome-wide significance. A different GWAS identified <italic>TMEM175</italic> (transmembrane protein 175), a lysosomal K+ channel, as a potential modifier gene in patients with Parkinson disease. Considering its role in modulating lysosomal pH, mutations in <italic>TMEM175</italic> are thought to further impair GCase activity as well as increase exogenous α-synuclein levels [<xref ref-type="bibr" rid="CR79">79</xref>]. Larger patient studies may aid in the identification of further relevant genetic modifiers. This can be accomplished by performing whole exome or genome sequencing of cohorts with Parkinson disease with and without <italic>GBA1</italic> mutations to see if those with <italic>GBA1</italic> mutations share other specific variants. Likewise, genomic sequencing of cohorts of older patients with Gaucher disease with and without parkinsonism may prove fruitful.</p>
<p id="Par63">Additionally, it remains unclear whether known Gaucher modifiers like prosaposin (<italic>PSAP)</italic> or LIMP2 (<italic>SCARB2)</italic> also play a role in patients with <italic>GBA1</italic>-associated parkinsonism. Rothaug et al. [<xref ref-type="bibr" rid="CR80">80</xref>] have shown that mice featuring a double knockout of the lysosomal targeting gene <italic>SCARB2</italic> exhibit elevated levels of GluCer, α-synuclein accumulation and dopaminergic neurodegeneration. However, further clinical studies are required to confirm this putative connection in human subjects. While recent reviews have extensively summarized the role of various lysosomal genes and mutations involved in Parkinson pathogenesis identified through methods such as GWAS and family studies (including <italic>SCARB2, LRRK2, SMPD1, PARK2, PINK1, PARK7</italic>, and others), apart from <italic>SCARB2</italic>, the potential interactions between these genes and <italic>GBA1</italic> on overall lysosomal function remain relatively uncharacterized [<xref ref-type="bibr" rid="CR81">81</xref>–<xref ref-type="bibr" rid="CR83">83</xref>].</p>
<p id="Par64">Finally, there is a strong possibility that epigenetics plays a role in susceptibility to Parkinson disease by modulating the <italic>GBA1</italic> gene. Epigenetics, known as the post-transcriptional modification of genetic expression, has been implicated in complex neurological disorders such as Alzheimer disease via histone acetylation of <italic>BACE1</italic>, or schizophrenia via hypomethylation of <italic>COMT</italic> [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. While no published epigenetic studies of Gaucher-associated Parkinson disease exist to date, they may provide insight as to how siblings with the same <italic>GBA1</italic> genotype may develop discordant parkinsonian phenotypes [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>].</p>
</sec>
<sec id="Sec13">
<title>Modelling Gaucher disease in vivo and in vitro</title>
<p id="Par65">Many approaches are utilized to study the pathological alterations driven by deficient GCase. Yet, the relationship between Gaucher mutations and the increased risk for Parkinson disease remains unclear. Many of the animal and non-animal models developed to study Gaucher-associated Parkinson disease (GD-PD) pathology have contributed significant information about different aspects of these diseases.</p>
<p id="Par66">Researchers have turned to vertebrate and non-vertebrate models of <italic>GBA1</italic>-associated parkinsonism to address selected, unresolved topics, such as the specific role of the GCase pathway in Parkinson pathogenesis and to test novel treatments for Gaucher disease. While animal models have inherent limitations, they remain useful, for the animal’s environment and genetics can be manipulated while still partially recapitulating the complex neural system of humans complex neural system. However, these diverse models fail to replicate the human brain’s complex cognitive and motor interconnections. Other promising models that that offer a way to elucidate possible pathogenic mechanisms are neurologic models derived from patient cells using the pluripotent reprogramming approaches developed by Yamanaka et al. [<xref ref-type="bibr" rid="CR88">88</xref>]. Overall, current GD-PD models often face an issue of prioritization between achieving desired Parkinson-like phenotypes or maintaining a realistic <italic>gba</italic> genotype. Modeling susceptibility to Parkinson disease, let alone Gaucher-associated Parkinson disease, remains exceedingly difficult for these reasons.</p>
</sec>
<sec id="Sec14">
<title><italic>GBA1</italic>-associated Parkinson models in diverse non-vertebrate organisms</title>
<p id="Par67">Non-vertebrate organisms such as <italic>Caenorhabditis elegans</italic>, (worms) <italic>Drosophila melanogaster</italic> (fruitfly<italic>)</italic> and the vertebrate fish, <italic>Oryzias latipes</italic> (medaka) have been used to demonstrate the relationship between Gaucher disease and Parkinson disease. One remarkable advantage of these models over mouse models is that animals homozygous for the null <italic>gba</italic> allele remain viable, rather than exhibiting a neonatal lethal phenotype [<xref ref-type="bibr" rid="CR89">89</xref>]. <italic>C. elegans</italic> are used to evaluate movement disorders because of their simple neurological system, transparent body and easily observable and stereotyped motor behavior [<xref ref-type="bibr" rid="CR90">90</xref>]. <italic>C. elegans</italic> with depleted GCase activity do exhibit higher α-synuclein levels than their wildtype counterparts [<xref ref-type="bibr" rid="CR51">51</xref>], resembling what is observed in human cellular models and mouse models. <italic>GBA1</italic> orthologs in <italic>D. melanogaster</italic> located on chromosome 3 (<italic>dGBA1a</italic> and <italic>dGBA1b</italic>), encoding proteins with ~ 31% and ~ 49% homology to human GCase, respectively, provide enough similarity to create a Gaucher-like condition when altered [<xref ref-type="bibr" rid="CR91">91</xref>]. Mutations in either of these orthologs creates a truncated protein; compound heterozygous flies representing the human <italic>GBA1</italic> carrier status demonstrate an elevated UPR and decreased survival. Additionally, knock-in fly models expressing the human mutations N370S and L444P have been used to successfully characterize UPR activation and locomotor defects in the presence of mutated <italic>GBA1</italic> mRNA [<xref ref-type="bibr" rid="CR91">91</xref>]. Overexpression of the human transgene <italic>SNCA</italic><sup><italic>A53T</italic></sup> in animal models is a commonly used approach to exacerbate Parkinson disease progression in fly, mouse, and even macaque models. Knock-out flies deficient in <italic>gba</italic>, crossed with those carrying a <italic>SNCA</italic><sup>A53T</sup> transgene displayed increased α-synuclein aggregation, loss of dopaminergic neurons, negative geotaxis and eye defects [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. Knockouts of <italic>gba</italic> in medaka, a fish model, show a neuronopathic Gaucher disease-like pathology, along with elevated α-synuclein levels and abnormal swimming movement [<xref ref-type="bibr" rid="CR94">94</xref>]. Research utilizing these models has contributed valuable information regarding the role of the ubiquitin protease system and α-synuclein in Parkinson pathogenesis and seem to confirm, species wide, an evolutionarily conserved relationship between GCase and α-synuclein.</p>
</sec>
<sec id="Sec15">
<title>Genetically or chemically modified mouse models of <italic>GBA1</italic>-associated Parkinson</title>
<p id="Par68">A great deal of work has gone into characterizing mouse models of GD-PD, created by knocking out or knocking down GCase activity. GCase impairment in mouse models is accomplished in two ways: genetic or chemical [<xref ref-type="bibr" rid="CR95">95</xref>].</p>
<p id="Par69">While genetic mouse models remain the more popular of the two methods, different shortcomings prevent any one model from exhibiting an accurate <italic>GBA1</italic>-associated parkinsonian phenotype. Due to the wide range in <italic>GBA1</italic> genotypes encountered in patients with Parkinson disease, researchers have attempted to introduce a battery of <italic>gba</italic> genotypes to model GD<italic>-</italic>PD, primarily based upon commonality, pathogenicity, and known neurological manifestations associated with human mutations. Both heterozygous and homozygous mutant models have been used to emulate <italic>GBA1</italic> carriers and patients with Gaucher disease, respectively. Examples of heterozygous GD<italic>-</italic>PD mice include the L444P/+, KO/+, and D409H/+ models, amongst others [<xref ref-type="bibr" rid="CR96">96</xref>–<xref ref-type="bibr" rid="CR98">98</xref>]. Unfortunately, these “carrier” mice do not exhibit Gaucher or Parkinson-like phenotypes, and so more severe, homozygous models are used instead. These models have displayed pathological alterations reminiscent of Parkinson disease, such as α-synuclein accumulation, dopaminergic neurodegeneration and motor impairment. Another approach to model GD-PD is to cross <italic>gba</italic> mutation-carrying mice with an established model of parkinsonism, such as mice overexpressing the human transgene <italic>SNCA</italic><sup><italic>A53T</italic></sup> [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. In addition to impaired GCase, these compound mutant mice exhibit an accelerated rate of α-synuclein accumulation, and an accelerated Parkinson-like phenotype. An example is crosses between the <italic>gba1</italic> D409H/D409H mouse and the <italic>SNCA</italic><sup>A53T</sup> mouse. The double mutant mice display substantia nigra-specific neurodegeneration, an increase in α-synuclein levels, and impaired memory and motor behavior [<xref ref-type="bibr" rid="CR52">52</xref>]. Another murine example, generated by administrating the substantia nigra-specific neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to L444P/+ mice, demonstrate more severe Parkinson-like pathology than mice created by either mechanism alone [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR99">99</xref>].</p>
<p id="Par70">Chemically inducing a Gaucher-like phenotype through the administration of CBE, a direct GCase competitive inhibitor, is also employed to model Gaucher-like pathology [<xref ref-type="bibr" rid="CR89">89</xref>]. High doses of CBE, thought to model neuronopathic Gaucher disease, induce increased monomeric α-synuclein levels [<xref ref-type="bibr" rid="CR100">100</xref>]. Lower CBE doses over a sustained period of time more closely resemble <italic>GBA1</italic> mutation carriers, with approximately 50% residual GCase activity, and creates a more Parkinson-like phenotype, with increased oligomeric α-synuclein levels, brain-wide neurodegeneration, and microglial activation [<xref ref-type="bibr" rid="CR101">101</xref>]. CBE models have major limitations, as the inhibitor can impact upstream pathways and non-specific chemical targeting, but they remain useful in certain circumstances.</p>
</sec>
<sec id="Sec16">
<title>Development of human iPSC models of <italic>GBA1</italic>-associated parkinsonism</title>
<p id="Par71">The brain may be the most complex organ in the body, and its complexity limits access to neurospecific cell types for study. Yamanaka et al. [<xref ref-type="bibr" rid="CR88">88</xref>] introduced the ability to reprogram somatic cells into induced pluripotent stem cells (iPSC) with the capability to be differentiated into a variety of somatic cell types, including neural sub-types. The use of iPSC technology to study brain specific cell subtypes in a patient context has advanced our understanding of function and the uniqueness of the cellular interactions in many neurodegenerative diseases (reviewed in [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Patient and control iPSC lines to can be used to generate neural-specific cells [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>] either directly using chemical signals (SMAD) to produce iNeurons or indirectly through embryoid bodies that develop into early neuroepithelial progenitor cells [<xref ref-type="bibr" rid="CR106">106</xref>]. The iPSC approach to model human neurodegenerative diseases also provides a scalable system that can by-pass the limitation of availability of patient biopsy material, instead using readily available patient fibroblasts or blood cells to produce iPSCs. Disease can then be investigated in the genetic context of the patient’s cells, allowing exploration of both pathology and therapeutics. There are now many examples of iPSC models to probe neurodegenerative diseases [<xref ref-type="bibr" rid="CR107">107</xref>] including Gaucher disease [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR109">109</xref>] Parkinson disease [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR110">110</xref>] and Parkinson disease with <italic>GBA1</italic> heterozygosity [<xref ref-type="bibr" rid="CR111">111</xref>–<xref ref-type="bibr" rid="CR113">113</xref>].</p>
<p id="Par72">The iPSCs can be further differentiated to neural subtypes such as dopaminergic (DA) neurons, cortical neurons and radial glial cells [<xref ref-type="bibr" rid="CR114">114</xref>]. While it has been difficult to study progressive, adult-onset diseases because of limited access to brain tissue and/or specific cell populations, many investigators now use iPSC methodologies to tackle the intricacies of neurodegenerative disease. One focus of iPSC studies in Gaucher disease is to evaluate lysosomal trafficking and autophagy impairment [<xref ref-type="bibr" rid="CR115">115</xref>] and to reproduce pathologic hallmarks [<xref ref-type="bibr" rid="CR116">116</xref>]. In parkinsonism, investigators examined cortical and dopaminergic neurons as well as astrocytes derived from patient iPSCs. One such study revealed defective synaptic connectivity in a familial Parkinson model [<xref ref-type="bibr" rid="CR110">110</xref>]. Other iPSC models of parkinsonism have shown altered autophagic flow in DA neurons [<xref ref-type="bibr" rid="CR117">117</xref>], alterations of vesicle trafficking in neural progenitor cells [<xref ref-type="bibr" rid="CR118">118</xref>], impaired tau expression and alterations of mitochondrial function [<xref ref-type="bibr" rid="CR119">119</xref>] in cortical neurons and, finally, increased susceptibility to oxidative stress in astrocytes [<xref ref-type="bibr" rid="CR120">120</xref>]. In patient-specific iPSCs containing the <italic>LRRK2</italic> G2019S mutation, Domenico et al. (2019) reported dysfunctional chaperone-mediated autophagy and progressive accumulation of α- synuclein in iPSC-derived astrocytes [<xref ref-type="bibr" rid="CR121">121</xref>]. Patient-derived iPSC disease models are now an evolving resource that may contribute unique insights into understanding progressive, adult-onset neurodegenerative diseases [<xref ref-type="bibr" rid="CR122">122</xref>] like parkinsonism and lysosomal storage disorders. Another recent in vitro research approach to investigate human brain function is brain organoids [<xref ref-type="bibr" rid="CR123">123</xref>–<xref ref-type="bibr" rid="CR125">125</xref>]. These three-dimensional models rely on the pluripotent iPSCs to self-organize in vitro to neurological tissue structures. While organoids to date are largely representative of early fetal development, they have already shown utility in assessing microcephaly resulting from Zika virus expression [<xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR127">127</xref>]. As organoid protocols are refined and validated, genomic engineering approaches will be applied to generate organoids that will permit specific mutations to be evaluated in these more complex, neurospecific models [<xref ref-type="bibr" rid="CR128">128</xref>].</p>
</sec>
<sec id="Sec17">
<title>Prospects for treatment of <italic>GBA1</italic>-associated parkinsonism</title>
<p id="Par73">As discussed above, current treatments for Gaucher disease are ERT and SRT, both FDA-approved interventions designed to generate and maintain a more normal GCase-substrate ratio in patients. While these treatments have substantially improved the visceral symptoms of Gaucher disease, current forms of ERT fail to cross the blood-brain barrier, and as a result, do not prevent or reverse the neuronopathic manifestations of Gaucher disease [<xref ref-type="bibr" rid="CR4">4</xref>]. Considering the heavily implicated role of GCase in Parkinson pathogenesis, developing an effective treatment that can restore neural GCase levels could not only drastically improve the quality of life for patients with neuronopathic Gaucher disease, but could also potentially prevent Parkinson onset in patients susceptible to Gaucher-associated Parkinson disease or even idiopathic parkinsonism. Currently brain penetrant forms of SRT are in clinical trials for patients with Parkinson disease who are heterozygous carriers of <italic>GBA1</italic> mutations. However, there is not solid evidence that there is substrate accumulation in the brains of <italic>GBA1</italic> mutation carriers, and homozygotes are not included in the study. Currently, three types of novel treatments are being investigated in addition to ERT and SRT (Fig. <xref ref-type="fig" rid="Fig4">4</xref>).</p>
</sec>
<sec id="Sec18">
<title>Gene therapy</title>
<p id="Par74">One possible mechanism to overcome the blood-brain barrier is the direct delivery of corrected genetic material to the affected tissue, otherwise known as gene therapy. While a variety of viral vectors are available, the most common type used in relation to <italic>GBA1</italic> is adeno-associated viral infection (AAV). AAV owes its popularity due to its ability to reliably deliver corrected DNA into chromosome 19 of the cell through non-pathogenic infection with nearly perfect specificity, reducing the need to implant excessive copies of the correctional gene into the cell [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR130">130</xref>]. AAV-mediated delivery of <italic>GBA1</italic>, otherwise known as AAV-<italic>GBA1</italic>, has been tested in animal models to assess its effect on Gaucher and/or Parkinson biomarker levels [<xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR132">132</xref>]. Regardless of the <italic>gba</italic> genotype, murine brain hemispheres injected with AAV-<italic>GBA1</italic> demonstrated improved GCase activity, decreased GluCer and GluSph and lowering of α-synuclein levels, and exhibited decreased neurodegeneration and neuroinflammation, compared to the complementary brain hemisphere injected with vehicle only [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR132">132</xref>–<xref ref-type="bibr" rid="CR134">134</xref>]. Massaro et al. [<xref ref-type="bibr" rid="CR132">132</xref>], using WT, KO/+, and conditional KO/KO mice, also demonstrated that early therapeutic intervention via AAV9-GBA1 drastically improved the mouse lifespan and GCase activity and decreased GluCer substrate levels. While AAV9-GBA1 did not completely rescue the mouse’s phenotype, it clearly ameliorated many of the murine symptoms. Ultrasound-guided in <italic>utero</italic> delivery in fetal mice and macaque brains similarly stabilized symptoms such as motor coordination and long-term microglial and astrocyte activation [<xref ref-type="bibr" rid="CR132">132</xref>]. While this method carries great potential as a single-dose, long-term solution to neuronopathic Gaucher disease, in mice it was found to work best with in <italic>utero</italic> or neonatal administration, as neurons subsequently have limited regenerative capacities [<xref ref-type="bibr" rid="CR132">132</xref>].</p>
</sec>
<sec id="Sec19">
<title>Therapy with pharmacological chaperones</title>
<p id="Par75">Chemical chaperones, small molecules that stabilize and refold misfolded proteins, are small enough to effectively cross the blood-brain barrier, making them a promising candidate for therapeutic research. Pharmacological chaperones may be able to stabilize misfolded GCase in the ER, knock down initiation of UPR and ER stress responses, and thus suppress apoptosis and mitochondria dysfunction [<xref ref-type="bibr" rid="CR135">135</xref>]. A GCase chaperone may also facilitate post-ER trafficking to the lysosome, enhancing delivery of mutated GCase protein to the lysosome where there may still be adequate GCase activity [<xref ref-type="bibr" rid="CR135">135</xref>]. Molecular chaperones are separated into two broad categories depending on their mechanism: extrinsic and intrinsic. Small molecule chaperones of GCase can be further separated into chaperones that bind to the active site as competitive inhibitors, or non-inhibitory chaperones that primarily enhance enzymatic activity.</p>
<p id="Par76">Extrinsic chaperone proteins serve to stabilize and refold proteins during periods of extreme stress that disrupt proteostasis, such as heat shock, cold, UV light, hypoxia, or wound healing. Members of the heat shock protein 70 (Hsp70) family are essential for proper GCase and lysosomal function and are known to work with co-chaperones such as TCP1 to identify and refold mutated GCase [<xref ref-type="bibr" rid="CR136">136</xref>]. Evidence suggests that administrating chemical chaperones to elevate endogenous chaperone protein levels may provide the key to refolding GCase and restoring normal enzymatic activities in the brain. Arimoclomol, one such chemical compound, induces the heat shock response, thereby amplifying Hsp70 and other heat shock proteins. Administering arimoclomol to fibroblasts derived from patients with genotype L444P/L444P improved GCase activity at a rate similar to approximately one unit of the standard ERT drug, alglucerase [<xref ref-type="bibr" rid="CR136">136</xref>]. A similar molecular chaperone, celastrol, acts by stabilizing the BAG protein family regulator 3 (BAG3) to refold mutant GCase [<xref ref-type="bibr" rid="CR85">85</xref>].</p>
<p id="Par77">Intrinsic chaperone proteins are chemical compounds that serve to directly stabilize misfolded GCase in the ER, allowing more functional proteins to form that can evade the ER-associated degradation pathway. Ideally, these small molecules selectively bind to mutant GCase at the neutral pH of the cytosol, and then lose their binding affinity as the enzyme enters the acidic pH of the lysosome. Ambroxol, one such chemical compound, was selected as a candidate chaperone protein identified from high-throughput screening of an FDA-approved chemical library composed of 1040 compounds [<xref ref-type="bibr" rid="CR137">137</xref>]. Administering ambroxol to patient-derived mutant <italic>GBA1</italic> cell lines rescued GCase activity and increased GCase levels on a dose-dependent basis [<xref ref-type="bibr" rid="CR138">138</xref>]. While murine Gaucher models have responded favorably to ambroxol administration, Parkinson related symptomology does not seem to be affected [<xref ref-type="bibr" rid="CR138">138</xref>]. L444P/+ mice treated with oral ambroxol for 12 days exhibited increased GCase levels compared to vehicle controls, but there was no change in α-synuclein levels [<xref ref-type="bibr" rid="CR139">139</xref>]. NCGC607, a small-molecule noninhibitory chaperone of GCase, is another chaperone protein identified by high-throughput screening. Administration of NCGC607 to iPSC-derived dopaminergic neurons from patients with both Gaucher disease and Parkinson disease showed that the chaperone protein was able to reduce substrate accumulation and improve GCase activity levels, highlighting its potential as an effective therapeutic. Interestingly, NCGC607 administration was also able to decrease α-synuclein levels in the neurons derived from patients with parkinsonism, suggesting this compound’s potential utility as a treatment for parkinsonism [<xref ref-type="bibr" rid="CR140">140</xref>]. Mazzulli et al. [<xref ref-type="bibr" rid="CR141">141</xref>] reported that increasing GCase activity by administration of a different non-inhibitory small molecule chaperone, NCGC758, resulted in α-synuclein clearance regardless of <italic>GBA1</italic> mutation status. Lastly, isofagomine (IFG) is an aza-sugar has also been evaluated as a chaperone protein, binding to both the wild-type and mutant versions of GCase. Cell lines from patients with missense <italic>GBA1</italic> mutations showed markedly improved GCase levels after incubation with IFG. While no mouse study has been conducted to investigate the impact of IFG on parkinsonian manifestations, transgenic mouse models homozygous for missense <italic>gba</italic> mutations have shown an improvement in overall organ size and GCase activity after IFG treatment [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR143">143</xref>]. Thus, from preliminary data, pharmacological chaperones represent a potential therapeutic approach for altering GCase activity by assisting in clearing the cell of early α-synuclein accumulation.</p>
<p id="Par78">Overall, pharmacological chaperone therapy presents some advantages over the current standard of care treatments for Gaucher disease, ERT and SRT. In addition to potentially being able to cross the blood-brain barrier, small molecular compounds are less expensive to manufacture, and can be taken orally instead of through intravenous infusions. From preliminary data, pharmacological chaperones could represent a potential therapeutic approach for preventing early α-synuclein accumulation. However, chaperone proteins only stabilize and improve the performance of misfolded GCase protein; thus, its use may be limited in the case of null mutations such as c.84insG. Furthermore, chaperone proteins have difficulty refolding L444P mutated GCase, because the altered amino acid lies outside the catalytic domain of the protein, in the immunoglobin domain [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]. Administering a chaperone that directly binds to this non-catalytic domain could rectify this issue, but brings into question whether specific chaperone proteins are required for each domain of GCase, and by extension each <italic>GBA1</italic> genotype. However, the potential benefits that chaperone therapy provides for patients with a missense <italic>GBA1</italic> mutation (representing the majority of patients) deserve consideration.</p>
</sec>
<sec id="Sec20">
<title>Histone deacetylase inhibitors</title>
<p id="Par79">Another class of small molecules that may serve to stabilize mutant GCase are histone deacetylase inhibitors (HIDACis), known for their effect on proteostasis [<xref ref-type="bibr" rid="CR145">145</xref>]. Histone deacetylase proteins (HDACs) operate through post-transcriptional modification of histones, transcriptional modifiers, and chaperone proteins. These processes are significantly upregulated in patients with Gaucher disease [<xref ref-type="bibr" rid="CR146">146</xref>]. Specifically, HIDACs have been shown to remove acetyl moieties from Hsp70, Hsp90, and tubulin, thereby enhancing their activity [<xref ref-type="bibr" rid="CR147">147</xref>]. Heat shock proteins such as Hsp70 and Hsp90 display remarkably diverse functions, where in addition to stabilizing misfolded proteins, they also stabilize proteasome complexes to direct UPR-related degradation. Inhibiting this process through HIDACis inhibits Hsp90’s ability to direct protein degradation, preventing recognition and degradation of mutant GCase, thereby increasing its quantity and catalytic activity in fibroblasts cell lines [<xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR148">148</xref>]. The administration of two HDACis, suberoylanilide hydroxamic acid (vorinostat) and LB-205, ameliorated the performance of fibroblasts derived from patients with Gaucher disease, along with other lysosomal storage disorders such as Niemann-Pick Type C disease [<xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR148">148</xref>–<xref ref-type="bibr" rid="CR150">150</xref>].</p>
</sec>
</sec>
<sec id="Sec21">
<title>Conclusions</title>
<p id="Par80">The link between <italic>GBA1</italic> and parkinsonism was surprising, and only recognized because of clinical findings that led to this association between a rare and common disorder. Despite a wealth of knowledge concerning the structure and function of glucocerebrosidase, our understanding of the role of this enzyme in Parkinson pathogenesis remains incomplete. Clearly there is an inverse relationship between levels of glucocerebrosidase and α-synuclein, suggesting that therapeutics aimed at enhancing glucocerebrosidase levels may have utility in the treatment of Parkinson disease. These are exciting times for those in the Gaucher field, because the increased attention focusing on glucocerebrosidase is also likely to yield new therapies for patients with Gaucher disease. Further exploration into potential genetic modifiers and epigenetic modifications will likely enhance our understanding of the role of this lysosomal protein in the etiology of Parkinson disease.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AAV</term>
<def>
<p id="Par3">Adeno-associated virus</p>
</def>
</def-item>
<def-item>
<term>BAG3</term>
<def>
<p id="Par4">BAG protein family regulator 3</p>
</def>
</def-item>
<def-item>
<term>BIN1</term>
<def>
<p id="Par5">Bridging integrator 1</p>
</def>
</def-item>
<def-item>
<term>CBE</term>
<def>
<p id="Par6">Conduritol–β-epoxide</p>
</def>
</def-item>
<def-item>
<term>CMA</term>
<def>
<p id="Par7">Chaperone mediated autophagy</p>
</def>
</def-item>
<def-item>
<term>ER</term>
<def>
<p id="Par8">Endoplasmic reticulum</p>
</def>
</def-item>
<def-item>
<term>ERT</term>
<def>
<p id="Par9">Enzyme Replacement Therapy</p>
</def>
</def-item>
<def-item>
<term>GalCer</term>
<def>
<p id="Par10">Galactosylceramide</p>
</def>
</def-item>
<def-item>
<term>
<italic>GBA1</italic>
</term>
<def>
<p id="Par11">Glucosylceramidase Beta 1</p>
</def>
</def-item>
<def-item>
<term>GCase</term>
<def>
<p id="Par12">Glucocerebrosidase</p>
</def>
</def-item>
<def-item>
<term>GD-PD</term>
<def>
<p id="Par13">Gaucher-Parkinson</p>
</def>
</def-item>
<def-item>
<term>GlcCer</term>
<def>
<p id="Par14">Glucosylceramide</p>
</def>
</def-item>
<def-item>
<term>GlcChol</term>
<def>
<p id="Par15">Glycosylated Cholesterol</p>
</def>
</def-item>
<def-item>
<term>GlcSph</term>
<def>
<p id="Par16">Glucosylsphingosine</p>
</def>
</def-item>
<def-item>
<term>HDAC</term>
<def>
<p id="Par17">Histone deacetylase</p>
</def>
</def-item>
<def-item>
<term>HDACi</term>
<def>
<p id="Par18">Histone deacetylase inhibitor</p>
</def>
</def-item>
<def-item>
<term>Hsp</term>
<def>
<p id="Par19">Heat shock protein</p>
</def>
</def-item>
<def-item>
<term>IFG</term>
<def>
<p id="Par20">Isofagamine</p>
</def>
</def-item>
<def-item>
<term>iPSC</term>
<def>
<p id="Par21">induced pluripotent stem cells</p>
</def>
</def-item>
<def-item>
<term>LAMP2a</term>
<def>
<p id="Par22">Lysosome-associated membrane protein 2a</p>
</def>
</def-item>
<def-item>
<term><italic>LIMP2</italic>/SCARB2</term>
<def>
<p id="Par23">Lysosomal Integrated Membrane Protein 2/Scavenger Receptor Class B Member 2</p>
</def>
</def-item>
<def-item>
<term>MPTP</term>
<def>
<p id="Par24">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</p>
</def>
</def-item>
<def-item>
<term>
<italic>MTX1</italic>
</term>
<def>
<p id="Par25">Metaxin1</p>
</def>
</def-item>
<def-item>
<term>PARK2</term>
<def>
<p id="Par26">E3 ubiquitin-protein ligase parkin</p>
</def>
</def-item>
<def-item>
<term>PINK1</term>
<def>
<p id="Par27">PTEN-induced kinase 1</p>
</def>
</def-item>
<def-item>
<term>PSAP</term>
<def>
<p id="Par28">Prosaposin</p>
</def>
</def-item>
<def-item>
<term>ROS</term>
<def>
<p id="Par29">reactive oxygen species</p>
</def>
</def-item>
<def-item>
<term>
<italic>SCNA</italic>
</term>
<def>
<p id="Par30">Alpha-synuclein gene</p>
</def>
</def-item>
<def-item>
<term>SRT</term>
<def>
<p id="Par31">Substrate Reduction Therapy</p>
</def>
</def-item>
<def-item>
<term>TFEB</term>
<def>
<p id="Par32">Transcription Factor EB</p>
</def>
</def-item>
<def-item>
<term>TIM</term>
<def>
<p id="Par33">Triosephosphate isomerase</p>
</def>
</def-item>
<def-item>
<term>TMEM175</term>
<def>
<p id="Par34">Transmembrane protein 175</p>
</def>
</def-item>
<def-item>
<term>TPS3</term>
<def>
<p id="Par35">Thrombospondin 3</p>
</def>
</def-item>
<def-item>
<term>UPR</term>
<def>
<p id="Par36">Unfolded protein response</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Publisher’s Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
<fn>
<p>Jenny Do and Cindy McKinney contributed equally to this work.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>This research was supported by the Intramural Research Program of the National Human Genome Research Institute and the National Institutes of Health.</p>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>Each author has made substantial contributions to the conception drafting and editing of this work and has approved the submitted version.</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>Not applicable.</p>
</notes>
<notes>
<title>Ethics approval and consent to participate</title>
<p id="Par81">Not applicable.</p>
</notes>
<notes>
<title>Consent for publication</title>
<p id="Par82">Not applicable.</p>
</notes>
<notes notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par83">The authors declare that they have no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Gaucher</surname>
<given-names>P</given-names>
</name>
</person-group>
<source/>De l’epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucmie
          <year>1882</year>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Oberling</surname>
<given-names>C</given-names>
</name>
</person-group>
<source/>Rev franc de Ped III
          <year>1927</year>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brady</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Kanfer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The metabolism of Glucocerebrosides. I. Purification and properties of a Glucocerebroside-cleaving enzyme from spleen tissue</article-title>
<source/>J Biol Chem
          <year>1965</year>
<volume>240</volume>
<fpage>39</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">14253443</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mistry</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Schiffmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Barton</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Weinreb</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Gaucher disease: Progress and ongoing challenges</article-title>
<source/>Mol Genet Metab
          <year>2017</year>
<volume>120</volume>
<issue>1–2</issue>
<fpage>8</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2016.11.006</pub-id>
<pub-id pub-id-type="pmid">27916601</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ginns</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Choudary</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Tsuji</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stubblefield</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sawyer</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene mapping and leader polypeptide sequence of human glucocerebrosidase: implications for Gaucher disease</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1985</year>
<volume>82</volume>
<issue>20</issue>
<fpage>7101</fpage>
<lpage>7105</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.82.20.7101</pub-id>
<pub-id pub-id-type="pmid">3863141</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reczek</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schwake</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schroder</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Blanz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase</article-title>
<source/>Cell
          <year>2007</year>
<volume>131</volume>
<issue>4</issue>
<fpage>770</fpage>
<lpage>783</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.10.018</pub-id>
<pub-id pub-id-type="pmid">18022370</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamargo</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Velayati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Goldin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The role of saposin C in Gaucher disease</article-title>
<source/>Mol Genet Metab
          <year>2012</year>
<volume>106</volume>
<issue>3</issue>
<fpage>257</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2012.04.024</pub-id>
<pub-id pub-id-type="pmid">22652185</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reiner</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Wigderson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Horowitz</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Structural analysis of the human glucocerebrosidase genes</article-title>
<source/>DNA
          <year>1988</year>
<volume>7</volume>
<issue>2</issue>
<fpage>107</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1089/dna.1988.7.107</pub-id>
<pub-id pub-id-type="pmid">3359914</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winfield</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Tayebi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Ginns</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease</article-title>
<source/>Genome Res
          <year>1997</year>
<volume>7</volume>
<fpage>1020</fpage>
<lpage>1026</lpage>
<pub-id pub-id-type="doi">10.1101/gr.7.10.1020</pub-id>
<pub-id pub-id-type="pmid">9331372</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stenson</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Mort</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Shiel</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>NS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human gene mutation database (HGMD): 2003 update</article-title>
<source/>Hum Mutat
          <year>2003</year>
<volume>21</volume>
<issue>6</issue>
<fpage>577</fpage>
<lpage>581</lpage>
<pub-id pub-id-type="doi">10.1002/humu.10212</pub-id>
<pub-id pub-id-type="pmid">12754702</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hruska</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>LaMarca</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)</article-title>
<source/>Hum Mutat
          <year>2008</year>
<volume>29</volume>
<issue>5</issue>
<fpage>567</fpage>
<lpage>583</lpage>
<pub-id pub-id-type="doi">10.1002/humu.20676</pub-id>
<pub-id pub-id-type="pmid">18338393</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tayebi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Stubblefield</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Orvisky</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>LaMarca</surname>
<given-names>ME</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease</article-title>
<source/>Am J Hum Genet
          <year>2003</year>
<volume>72</volume>
<issue>3</issue>
<fpage>519</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="doi">10.1086/367850</pub-id>
<pub-id pub-id-type="pmid">12587096</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parkin</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Brunning</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>Pathology of the Gaucher cell</article-title>
<source/>Prog Clin Biol Res
          <year>1982</year>
<volume>95</volume>
<fpage>151</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="pmid">7122633</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taddei</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Kacena</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Malhotra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boxer</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients</article-title>
<source/>Am J Hematol
          <year>2009</year>
<volume>84</volume>
<issue>4</issue>
<fpage>208</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="doi">10.1002/ajh.21362</pub-id>
<pub-id pub-id-type="pmid">19260119</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Oppenheim</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Kauvar</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Tayebi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity</article-title>
<source/>Blood Cells Mol Dis
          <year>2011</year>
<volume>46</volume>
<issue>1</issue>
<fpage>75</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcmd.2010.08.012</pub-id>
<pub-id pub-id-type="pmid">20880730</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pedoeim</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Groden</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The clinical management of type 2 Gaucher disease</article-title>
<source/>Mol Genet Metab
          <year>2015</year>
<volume>114</volume>
<issue>2</issue>
<fpage>110</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2014.11.008</pub-id>
<pub-id pub-id-type="pmid">25435509</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benko</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ries</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wiggs</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Schiffmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fitzgibbon</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<article-title>The saccadic and neurological deficits in type 3 Gaucher disease</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<issue>7</issue>
<fpage>e22410</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0022410</pub-id>
<pub-id pub-id-type="pmid">21799847</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barton</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Dambrosia</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Di Bisceglie</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Doppelt</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>SC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher’s disease</article-title>
<source/>N Engl J Med
          <year>1991</year>
<volume>324</volume>
<issue>21</issue>
<fpage>1464</fpage>
<lpage>1470</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM199105233242104</pub-id>
<pub-id pub-id-type="pmid">2023606</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mistry</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Lukina</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ben Turkia</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Amato</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Baris</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dasouki</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial</article-title>
<source/>Jama
          <year>2015</year>
<volume>313</volume>
<issue>7</issue>
<fpage>695</fpage>
<lpage>706</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2015.459</pub-id>
<pub-id pub-id-type="pmid">25688781</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gegg</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Shihabuddin</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Sardi</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Schapira</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>No evidence for substrate accumulation in Parkinson brains with GBA mutations</article-title>
<source/>Mov Disord
          <year>2015</year>
<volume>30</volume>
<issue>8</issue>
<fpage>1085</fpage>
<lpage>1089</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26278</pub-id>
<pub-id pub-id-type="pmid">26096906</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neudorfer</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Giladi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Elstein</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Abrahamov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Turezkite</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Aghai</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Occurrence of Parkinson's syndrome in type I Gaucher disease</article-title>
<source/>QJM
          <year>1996</year>
<volume>89</volume>
<issue>9</issue>
<fpage>691</fpage>
<lpage>694</lpage>
<pub-id pub-id-type="doi">10.1093/qjmed/89.9.691</pub-id>
<pub-id pub-id-type="pmid">8917744</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tayebi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Callahan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Madike</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Stubblefield</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Orvisky</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Krasnewich</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gaucher disease and parkinsonism: a phenotypic and genotypic characterization</article-title>
<source/>Mol Genet Metab
          <year>2001</year>
<volume>73</volume>
<issue>4</issue>
<fpage>313</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1006/mgme.2001.3201</pub-id>
<pub-id pub-id-type="pmid">11509013</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tayebi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stubblefield</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Orvisky</surname>
<given-names>E</given-names>
</name>
<name>
<surname>LaMarca</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?</article-title>
<source/>Mol Genet Metab
          <year>2003</year>
<volume>79</volume>
<issue>2</issue>
<fpage>104</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1016/S1096-7192(03)00071-4</pub-id>
<pub-id pub-id-type="pmid">12809640</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goker-Alpan</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Schiffmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>LaMarca</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Nussbaum</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>McInerney-Leo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Parkinsonism among Gaucher disease carriers</article-title>
<source/>J Med Genet
          <year>2004</year>
<volume>41</volume>
<issue>12</issue>
<fpage>937</fpage>
<lpage>940</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2004.024455</pub-id>
<pub-id pub-id-type="pmid">15591280</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lwin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Orvisky</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Goker-Alpan</surname>
<given-names>O</given-names>
</name>
<name>
<surname>LaMarca</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Glucocerebrosidase mutations in subjects with parkinsonism</article-title>
<source/>Mol Genet Metab
          <year>2004</year>
<volume>81</volume>
<issue>1</issue>
<fpage>70</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2003.11.004</pub-id>
<pub-id pub-id-type="pmid">14728994</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aharon-Peretz</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Gershoni-Baruch</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Mutations in the glucocerbrosidase gene and Parkinsons disease in Asheknazi Jews</article-title>
<source/>N Engl J Med
          <year>2004</year>
<volume>351</volume>
<fpage>1972</fpage>
<lpage>1977</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa033277</pub-id>
<pub-id pub-id-type="pmid">15525722</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nalls</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Aasly</surname>
<given-names>JO</given-names>
</name>
<name>
<surname>Aharon-Peretz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Annesi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Barbosa</surname>
<given-names>ER</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease</article-title>
<source/>N Engl J Med
          <year>2009</year>
<volume>361</volume>
<issue>17</issue>
<fpage>1651</fpage>
<lpage>1661</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa0901281</pub-id>
<pub-id pub-id-type="pmid">19846850</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aflaki</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Westbroek</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The complicated relationship between Gaucher disease and parkinsonism: insights from a rare disease</article-title>
<source/>Neuron
          <year>2017</year>
<volume>93</volume>
<issue>4</issue>
<fpage>737</fpage>
<lpage>746</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2017.01.018</pub-id>
<pub-id pub-id-type="pmid">28231462</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan-Or</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Amshalom</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kilarski</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Bar-Shira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gana-Weisz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mirelman</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential effects of severe vs mild GBA mutations on Parkinson disease</article-title>
<source/>Neurobiology
          <year>2015</year>
<volume>84</volume>
<issue>9</issue>
<fpage>880</fpage>
<lpage>887</lpage>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mallett</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Alcalay</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Ambalavanan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dion</surname>
<given-names>PA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GBA p.T369M substitution in Parkinson disease: Polymorphism or association? A meta-analysis</article-title>
<source/>Neurol Genet
          <year>2016</year>
<volume>2</volume>
<issue>5</issue>
<fpage>e104</fpage>
<pub-id pub-id-type="doi">10.1212/NXG.0000000000000104</pub-id>
<pub-id pub-id-type="pmid">27648471</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenbloom</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Balwani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bronstein</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kolodny</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sathe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gwosdow</surname>
<given-names>AR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The incidence of parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher registry</article-title>
<source/>Blood Cells Mol Dis
          <year>2011</year>
<volume>46</volume>
<issue>1</issue>
<fpage>95</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcmd.2010.10.006</pub-id>
<pub-id pub-id-type="pmid">21067946</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machaczka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rucinska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Skotnicki</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Jurczak</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Parkinson’s syndrome preceding clinical manifestation of Gaucher’s disease</article-title>
<source/>Am J Hematol
          <year>1999</year>
<volume>61</volume>
<fpage>216</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8652(199907)61:3&lt;216::AID-AJH12&gt;3.0.CO;2-B</pub-id>
<pub-id pub-id-type="pmid">10398575</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bultron</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kacena</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Boxer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sathe</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The risk of Parkinson's disease in type 1 Gaucher disease</article-title>
<source/>J Inherit Metab Dis
          <year>2010</year>
<volume>33</volume>
<issue>2</issue>
<fpage>167</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-010-9055-0</pub-id>
<pub-id pub-id-type="pmid">20177787</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alcalay</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Dinur</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sakanaka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes</article-title>
<source/>JAMA
          <year>2014</year>
<volume>71</volume>
<issue>6</issue>
<fpage>752</fpage>
<lpage>757</lpage>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duran</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mencacci</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Angeli</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Shoai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Deas</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher’s disease</article-title>
<source/>Mov Disord
          <year>2012</year>
<volume>28</volume>
<issue>2</issue>
<fpage>232</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1002/mds.25248</pub-id>
<pub-id pub-id-type="pmid">23225227</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Gysbers</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Abbott</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Tayebi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease</article-title>
<source/>Brain
          <year>2014</year>
<volume>137</volume>
<fpage>834</fpage>
<lpage>848</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awt367</pub-id>
<pub-id pub-id-type="pmid">24477431</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gegg</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Heales</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>NW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains</article-title>
<source/>Ann Neurol
          <year>2012</year>
<volume>72</volume>
<issue>3</issue>
<fpage>455</fpage>
<lpage>463</lpage>
<pub-id pub-id-type="doi">10.1002/ana.23614</pub-id>
<pub-id pub-id-type="pmid">23034917</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luzio</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Hackmann</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dieckmann</surname>
<given-names>NMG</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>The Biogenesis of Lysosomes and Lysosome-Related Organelles</article-title>
<source/>Cold Spring Harbor Perspect Biol
          <year>2014</year>
<volume>6</volume>
<fpage>a016840</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a016840</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Settembre</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zoncu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Medina</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Vetrini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Erdin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Erdin</surname>
<given-names>SU</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB</article-title>
<source/>EMBO J
          <year>2012</year>
<volume>31</volume>
<fpage>1095</fpage>
<lpage>1108</lpage>
<pub-id pub-id-type="doi">10.1038/emboj.2012.32</pub-id>
<pub-id pub-id-type="pmid">22343943</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Boot</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Locascio</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>IE</given-names>
</name>
<name>
<surname>Winder-Rhodes</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Eberly</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson’s</article-title>
<source/>Ann Neurol
          <year>2016</year>
<volume>80</volume>
<issue>5</issue>
<fpage>674</fpage>
<lpage>685</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24781</pub-id>
<pub-id pub-id-type="pmid">27717005</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conway</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Lansbury</surname>
<given-names>PT</given-names>
</name>
</person-group>
<article-title>Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease</article-title>
<source/>Nat Med
          <year>1998</year>
<volume>4</volume>
<issue>11</issue>
<fpage>1318</fpage>
<lpage>1320</lpage>
<pub-id pub-id-type="doi">10.1038/3311</pub-id>
<pub-id pub-id-type="pmid">9809558</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polymeropoulos</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Lavedan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Leroy</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ide</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Dehejia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dutra</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutation in the α-Synuclein gene identified in families with Parkinson’s disease</article-title>
<source/>Science
          <year>1997</year>
<volume>276</volume>
<issue>5321</issue>
<fpage>2045</fpage>
<lpage>2047</lpage>
<pub-id pub-id-type="doi">10.1126/science.276.5321.2045</pub-id>
<pub-id pub-id-type="pmid">9197268</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spillantini</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</name>
<name>
<surname>Jakes</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Goedert</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Alpha-synuclein in Lewy bodies</article-title>
<source/>Nature
          <year>1997</year>
<volume>388</volume>
<issue>6645</issue>
<fpage>839</fpage>
<lpage>840</lpage>
<pub-id pub-id-type="doi">10.1038/42166</pub-id>
<pub-id pub-id-type="pmid">9278044</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartels</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Selkoe</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>A-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation</article-title>
<source/>Nature
          <year>2011</year>
<volume>477</volume>
<issue>7362</issue>
<fpage>107</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1038/nature10324</pub-id>
<pub-id pub-id-type="pmid">21841800</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lashuel</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Overk</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Oueslati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The many faces of α-synuclein: from structure and toxicity to therapeutic target</article-title>
<source/>Nat Rev Neurosci
          <year>2013</year>
<volume>14</volume>
<issue>1</issue>
<fpage>38</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3406</pub-id>
<pub-id pub-id-type="pmid">23254192</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Membrane-bound alpha-Synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>2002</volume>
<issue>1</issue>
<fpage>671</fpage>
<lpage>678</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M107045200</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benskey</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fredric</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Manfedsson</surname>
<given-names>FP</given-names>
</name>
</person-group>
<article-title>The contribution of alpha synuclein to neuronal survival and function—Implications for Parkinson’s disease</article-title>
<source/>J Neurochem
          <year>2016</year>
<volume>137</volume>
<fpage>331</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.13570</pub-id>
<pub-id pub-id-type="pmid">26852372</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mak</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>McCormack</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Manning-Boğ</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Cuervo</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>DAD</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Lysosomal degradation of α-Synuclein in vivo</article-title>
<source/>J Biol Chem
          <year>2010</year>
<volume>285</volume>
<fpage>13621</fpage>
<lpage>13629</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M109.074617</pub-id>
<pub-id pub-id-type="pmid">20200163</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kinghorn</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Asghari</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Castillo-Quan</surname>
<given-names>JI</given-names>
</name>
</person-group>
<article-title>The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson’s disease</article-title>
<source/>Neural Regen Res
          <year>2017</year>
<volume>12</volume>
<issue>3</issue>
<fpage>380</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="doi">10.4103/1673-5374.202934</pub-id>
<pub-id pub-id-type="pmid">28469644</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gunder</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Duran-Pacheco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zimmermann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ruf</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Moors</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bauman</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Path mediation analysis reveals GBA impacts Lewy body disease status by increasing alpha-synuclein levels</article-title>
<source/>Neurobiol Dis
          <year>2019</year>
<volume>121</volume>
<fpage>205</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2018.09.015</pub-id>
<pub-id pub-id-type="pmid">30236861</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazulli</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y-H</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>McClean</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>GA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogeneic loop in synucleinopathies</article-title>
<source/>Cell
          <year>2011</year>
<volume>146</volume>
<issue>1</issue>
<fpage>37</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2011.06.001</pub-id>
<pub-id pub-id-type="pmid">21700325</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Umanah</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Bandaru</surname>
<given-names>VVR</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GBA1 deficiency negatively affects physiological alpha-synuclein tetramers and related multimers</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2018</year>
<volume>115</volume>
<issue>4</issue>
<fpage>798</fpage>
<lpage>803</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1700465115</pub-id>
<pub-id pub-id-type="pmid">29311330</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franco</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sanchez-Arias</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Navano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lanciego</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Glucocerebrosidase mutations and synucleinopathies. Potential role of sterylglucosides and relevance of stuying both GBA1 and GBA2 genes</article-title>
<source/>Front Neuroanat
          <year>2018</year>
<volume>12</volume>
<fpage>52</fpage>
<pub-id pub-id-type="doi">10.3389/fnana.2018.00052</pub-id>
<pub-id pub-id-type="pmid">30002620</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marques</surname>
<given-names>ARA</given-names>
</name>
<name>
<surname>Mirzaian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Akiyama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wisse</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ferraz</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Gaspar</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular beta-glucosidases</article-title>
<source/>J Lipid Res
          <year>2016</year>
<volume>57</volume>
<issue>1</issue>
<fpage>451</fpage>
<lpage>463</lpage>
<pub-id pub-id-type="doi">10.1194/jlr.M064923</pub-id>
<pub-id pub-id-type="pmid">26724485</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gruschus</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Did alpha-Synuclein and glucocerebrosidase coevolve? Implications for Parkinson’s Disease</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<issue>7</issue>
<fpage>1</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0133863</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dvir</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Harel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Toker</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Silman</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Futerman</surname>
<given-names>AH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease</article-title>
<source/>EMBO Rep
          <year>2003</year>
<volume>4</volume>
<issue>7</issue>
<fpage>704</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="doi">10.1038/sj.embor.embor873</pub-id>
<pub-id pub-id-type="pmid">12792654</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grace</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Scheinker</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Berg-Fussman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grabowski</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression</article-title>
<source/>J Biol Chem
          <year>1994</year>
<volume>269</volume>
<fpage>2283</fpage>
<lpage>2291</lpage>
<pub-id pub-id-type="pmid">8294487</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Skinner</surname>
<given-names>OS</given-names>
</name>
<name>
<surname>Ysselstein</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Remis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lansbury</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>β-Glucocerebrosidase modulators promote dimerization of β-Glucocerebrosidase and reveal an allosteric binding site</article-title>
<source/>J Am Chem Soc
          <year>2018</year>
<volume>140</volume>
<issue>18</issue>
<fpage>5914</fpage>
<lpage>5924</lpage>
<pub-id pub-id-type="doi">10.1021/jacs.7b13003</pub-id>
<pub-id pub-id-type="pmid">29676907</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahn</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Rhim</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<fpage>12334</fpage>
<lpage>12342</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M110414200</pub-id>
<pub-id pub-id-type="pmid">11821392</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yap</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Gruschus</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Velayati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Westbroek</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Goldin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Moaven</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases</article-title>
<source/>J Biol Chem
          <year>2011</year>
<volume>286</volume>
<issue>32</issue>
<fpage>28080</fpage>
<lpage>28088</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.237859</pub-id>
<pub-id pub-id-type="pmid">21653695</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colla</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Coune</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pletnikova</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Troncoso</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Iwatsubo</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo</article-title>
<source/>J Neurosci
          <year>2012</year>
<volume>32</volume>
<issue>10</issue>
<fpage>3306</fpage>
<lpage>3320</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5367-11.2012</pub-id>
<pub-id pub-id-type="pmid">22399753</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Hartfield</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Christian</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Emmanoulidou</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Booth</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ER stress and Autophagic perturbations Lead to elevated extracellular alpha-Synuclein in GBA-N370S Parkinson's iPSC-derived dopamine neurons</article-title>
<source/>Stem Cell Reports
          <year>2016</year>
<volume>6</volume>
<issue>3</issue>
<fpage>342</fpage>
<lpage>356</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2016.01.013</pub-id>
<pub-id pub-id-type="pmid">26905200</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colla</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Pletnikova</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Troncoso</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Glabe</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo</article-title>
<source/>J Neurosci Off J Soc Neurosci
          <year>2012</year>
<volume>32</volume>
<issue>10</issue>
<fpage>3301</fpage>
<lpage>3305</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5368-11.2012</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shimoda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hanai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aizawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>2</volume>
<issue>8</issue>
<fpage>e69147</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0069147</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heman-Ackah</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Manzano</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hoozemans</surname>
<given-names>JJM</given-names>
</name>
<name>
<surname>Scheper</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Flynn</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Haerty</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alpha-synuclein induces the unfolded protein response in Parkinson’s disease SNCA triplication iPSC-derived neurons</article-title>
<source/>Hum Mol Genet
          <year>2017</year>
<volume>26</volume>
<issue>22</issue>
<fpage>4441</fpage>
<lpage>4450</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddx331</pub-id>
<pub-id pub-id-type="pmid">28973645</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zunke</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Moise</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Belur</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Gelyana</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Stojkovska</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dzaferbegovic</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reversible conformational conversion of alpha-synucelin into toxic assemblies by glucosylceramide</article-title>
<source/>Neuron
          <year>2018</year>
<volume>97</volume>
<fpage>92</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2017.12.012</pub-id>
<pub-id pub-id-type="pmid">29290548</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H-J</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S-J</given-names>
</name>
</person-group>
<article-title>Formation and removal of α-Synuclein aggregates in cells exposed to mitochondrial inhibitors</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<issue>7</issue>
<fpage>5411</fpage>
<lpage>5417</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M105326200</pub-id>
<pub-id pub-id-type="pmid">11724769</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Krainc</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Lysosomal trafficking defects link Parkinson’s disease with Gaucher’s disease</article-title>
<source/>Mov Disabil
          <year>2016</year>
<volume>31</volume>
<issue>11</issue>
<fpage>1610</fpage>
<lpage>1618</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26802</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Anandatheerthavarada</surname>
<given-names>HK</given-names>
</name>
</person-group>
<article-title>Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer's and Parkinson’s diseases</article-title>
<source/>Biochim Biophys Acta (BBA) - Mol Basis Dis
          <year>2010</year>
<volume>1802</volume>
<issue>1</issue>
<fpage>11</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2009.07.007</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Subramaniam</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Chesselet</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction and oxidative stress in Parkinson’s disease</article-title>
<source/>Prog Neurobiol
          <year>2013</year>
<volume>106</volume>
<fpage>17</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2013.04.004</pub-id>
<pub-id pub-id-type="pmid">23643800</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enquist</surname>
<given-names>IB</given-names>
</name>
<name>
<surname>Bianco</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Ooka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Månsson</surname>
<given-names>J-E</given-names>
</name>
<name>
<surname>Ehinger</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Murine models of acute neuronopathic Gaucher disease</article-title>
<source/>PNAS.
          <year>2007</year>
<volume>104</volume>
<issue>44</issue>
<fpage>17483</fpage>
<lpage>17488</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0708086104</pub-id>
<pub-id pub-id-type="pmid">17954912</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osellame</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Rahim</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Hargreaves</surname>
<given-names>IP</given-names>
</name>
<name>
<surname>Gegg</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Richard-Londt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brandner</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondria and quality control defects in a mouse model of Gaucher disease—links to Parkinson’s disease</article-title>
<source/>Cell Metab
          <year>2013</year>
<volume>17</volume>
<fpage>941</fpage>
<lpage>953</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2013.04.014</pub-id>
<pub-id pub-id-type="pmid">23707074</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gegg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schapira</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction associated with glucocerebrosidase deficiency</article-title>
<source/>Neurobiol Dis
          <year>2016</year>
<volume>90</volume>
<fpage>43</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2015.09.006</pub-id>
<pub-id pub-id-type="pmid">26388395</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rostovtseva</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Gurnev</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Protchenko</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hoogerheide</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Yap</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Philpott</surname>
<given-names>CC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Synuclein shows high affinity interaction with voltage- dependent Anion Channel, suggesting mechanisms of mitochondrial regulation and toxicity in Parkinson disease</article-title>
<source/>J Biochem
          <year>2015</year>
<volume>290</volume>
<issue>30</issue>
<fpage>18467</fpage>
<lpage>18477</lpage>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>Michaela E.</given-names>
</name>
<name>
<surname>Stecher</surname>
<given-names>Benjamin</given-names>
</name>
<name>
<surname>Labrie</surname>
<given-names>Viviane</given-names>
</name>
<name>
<surname>Brundin</surname>
<given-names>Lena</given-names>
</name>
<name>
<surname>Brundin</surname>
<given-names>Patrik</given-names>
</name>
</person-group>
<article-title>Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis</article-title>
<source/>Trends in Neurosciences
          <year>2019</year>
<volume>42</volume>
<issue>1</issue>
<fpage>4</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2018.09.007</pub-id>
<pub-id pub-id-type="pmid">30342839</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Tayebi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Exploring genetic modifiers of Gaucher disease: the next horizon</article-title>
<source/>Hum Mutat
          <year>2018</year>
<volume>39</volume>
<issue>12</issue>
<fpage>1739</fpage>
<lpage>1751</lpage>
<pub-id pub-id-type="doi">10.1002/humu.23611</pub-id>
<pub-id pub-id-type="pmid">30098107</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan-Or</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Bar-Shira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gurevich</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Giladi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Orr-Urtreger</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Homozygosity of the MTX1 c.184T&gt;A (P.S63T) alteration modifies the age of onset in GBA associate Parkinson’s Disease</article-title>
<source/>Neurogenetics
          <year>2011</year>
<volume>12</volume>
<issue>4</issue>
<fpage>325</fpage>
<lpage>332</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-011-0293-6</pub-id>
<pub-id pub-id-type="pmid">21837367</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan-Or</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Amshalom</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bar-Shira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gana-Weisz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mirelman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marder</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bressman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giladi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Orr-Urtreger</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease</article-title>
<source/>J Neurol
          <year>2015</year>
<volume>262</volume>
<fpage>2443</fpage>
<lpage>2447</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-015-7868-3</pub-id>
<pub-id pub-id-type="pmid">26233692</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jinn</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Drolet</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Cramer</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Toolan</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Gretzula</surname>
<given-names>CA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TMEM175 deficiency impairs lysosomal and mitochondrial function and increases alpha-synuclein aggregation</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2017</year>
<volume>114</volume>
<issue>9</issue>
<fpage>2389</fpage>
<lpage>2394</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1616332114</pub-id>
<pub-id pub-id-type="pmid">28193887</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothaug</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zunke</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mazzulli</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Schweizer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Altmeppen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lullmann-Rauch</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>LIMP-2 expression is critical for beta-glucocerebrosidase activity and alpha-synuclein clearance</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2014</year>
<volume>111</volume>
<issue>43</issue>
<fpage>15573</fpage>
<lpage>15578</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1405700111</pub-id>
<pub-id pub-id-type="pmid">25316793</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan-Or</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Dion</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Rouleau</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease</article-title>
<source/>Autophagy
          <year>2015</year>
<volume>11</volume>
<issue>9</issue>
<fpage>1443</fpage>
<lpage>1457</lpage>
<pub-id pub-id-type="doi">10.1080/15548627.2015.1067364</pub-id>
<pub-id pub-id-type="pmid">26207393</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beilina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cookson</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Genes associated with Parkinson’s disease: regulation of autophagy and beyond</article-title>
<source/>J Neurochem
          <year>2016</year>
<volume>139</volume>
<fpage>91</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.13266</pub-id>
<pub-id pub-id-type="pmid">26223426</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Ysselstein</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Severino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krainc</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Synaptic, mitochondrial, and lysosomal dysfunction in Parkinson’s disease</article-title>
<source/>Trends Neurosci
          <year>2019</year>
<volume>42</volume>
<issue>2</issue>
<fpage>140</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2018.11.001</pub-id>
<pub-id pub-id-type="pmid">30509690</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdolmaleky</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Faraone</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Wilcox</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Glatt</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder</article-title>
<source/>Hum Mol Genet
          <year>2006</year>
<volume>15</volume>
<issue>21</issue>
<fpage>3132</fpage>
<lpage>3145</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddl253</pub-id>
<pub-id pub-id-type="pmid">16984965</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Swallows</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>RO</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones</article-title>
<source/>PNAS
          <year>2014</year>
<volume>111</volume>
<issue>1</issue>
<fpage>249</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1321341111</pub-id>
<pub-id pub-id-type="pmid">24351928</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biegstraaten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van Schaik</surname>
<given-names>IN</given-names>
</name>
<name>
<surname>Aerts</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Langeveld</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mannens</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Bour</surname>
<given-names>LJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A monozygotic twin pair with highly discordant Gaucher phenotypes</article-title>
<source/>Blood Cells Mol Dis
          <year>2011</year>
<volume>46</volume>
<issue>1</issue>
<fpage>39</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcmd.2010.10.007</pub-id>
<pub-id pub-id-type="pmid">21056933</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lachmann</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Halsall</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>TM</given-names>
</name>
</person-group>
<article-title>Twin pairs showing discordance of phenotype in adult Gaucher’s disease</article-title>
<source/>Qjm
          <year>2004</year>
<volume>97</volume>
<issue>4</issue>
<fpage>199</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1093/qjmed/hch036</pub-id>
<pub-id pub-id-type="pmid">15028849</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamanaka</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Strategies and new developments in the generation of patient-specific pluripotent stem cells</article-title>
<source/>Cell Stem Cell
          <year>2007</year>
<volume>1</volume>
<issue>1</issue>
<fpage>39</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2007.05.012</pub-id>
<pub-id pub-id-type="pmid">18371333</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farfel-Becker</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vitner</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Futerman</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Animal models for Gaucher disease research</article-title>
<source/>Dis Model Mech
          <year>2011</year>
<volume>4</volume>
<issue>6</issue>
<fpage>746</fpage>
<lpage>752</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.008185</pub-id>
<pub-id pub-id-type="pmid">21954067</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dexter</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders</article-title>
<source/>Neurotherapeutics
          <year>2012</year>
<volume>9</volume>
<issue>2</issue>
<fpage>393</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="doi">10.1007/s13311-012-0109-x</pub-id>
<pub-id pub-id-type="pmid">22403010</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maor</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rencus-Lazar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Filocamo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Steller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Horowitz</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Unfolded protein response in Gaucher disease: from human to Drosophila</article-title>
<source/>Orphanet J Rare Dis
          <year>2013</year>
<volume>8</volume>
<fpage>140</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1172-8-140</pub-id>
<pub-id pub-id-type="pmid">24020503</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maor</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cabasso</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Krivoruk</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Steller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The contribution of mutant GBA to the development of Parkinson disease in Drosophila</article-title>
<source/>Hum Mol Genet
          <year>2016</year>
<volume>25</volume>
<issue>13</issue>
<fpage>2712</fpage>
<lpage>2727</lpage>
<pub-id pub-id-type="pmid">27162249</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abul-Khair</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Dhanushkodi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ardah</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>YF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Silencing of glucocerebrosidase gene in Drosophila enhances the aggregation of Parkinson’s disease associated alpha-synuclein mutant A53T and affects locomotor activity</article-title>
<source/>Front Neurosci
          <year>2018</year>
<volume>12</volume>
<fpage>81</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2018.00081</pub-id>
<pub-id pub-id-type="pmid">29503608</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uemura</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Koike</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ansai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ishikawa-Fujiwara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsui</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein</article-title>
<source/>PLoS Genet
          <year>2015</year>
<volume>11</volume>
<issue>4</issue>
<fpage>e1005065</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1005065</pub-id>
<pub-id pub-id-type="pmid">25835295</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farfel-Becker</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tayebi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?</article-title>
<source/>Trends Neurosci
          <year>2019</year>
<volume>1519</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>13</lpage>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tayebi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Parisiadoub</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Berhea</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gonzaleza</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Serra-Vinardella</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tamargoa</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Maniwanga</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sorrentinoc</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fujiwarad</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Greya</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hassana</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Blech-Hermonia</surname>
<given-names>YN</given-names>
</name>
<name>
<surname>Chenb</surname>
<given-names>C</given-names>
</name>
<name>
<surname>McGlincheye</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Makariou-Pikisb</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brooksc</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ginnsf</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Oryd</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Giassonc</surname>
<given-names>BI</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course</article-title>
<source/>Mol Genet Metab
          <year>2017</year>
<volume>122</volume>
<issue>4</issue>
<fpage>198</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2017.11.001</pub-id>
<pub-id pub-id-type="pmid">29173981</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Migdalska-Richards</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wegrzynowicz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rusconi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Deangeli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Di Monte</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Spillantini</surname>
<given-names>MG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice</article-title>
<source/>Brain
          <year>2017</year>
<volume>140</volume>
<issue>10</issue>
<fpage>2706</fpage>
<lpage>2721</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awx221</pub-id>
<pub-id pub-id-type="pmid">28969384</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>SangMin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Seok</surname>
<given-names>KH</given-names>
</name>
</person-group>
<article-title>D409H GBA1 mutation accelerates the progression of pathology in A53T alpha-synuclein transgenic mouse model</article-title>
<source/>Acta Neuropathol Commun
          <year>2018</year>
<volume>6</volume>
<fpage>32</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1186/s40478-018-0538-9</pub-id>
<pub-id pub-id-type="pmid">29703245</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hamler</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ex vivo and in vivo effects of isofagomine on acid beta-glucosidase variants and substrate levels in Gaucher disease</article-title>
<source/>J Biol Chem
          <year>2012</year>
<volume>287</volume>
<issue>6</issue>
<fpage>4275</fpage>
<lpage>4287</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.280016</pub-id>
<pub-id pub-id-type="pmid">22167193</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manning-Bog</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Schule</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Langston</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism</article-title>
<source/>Neurotoxicology
          <year>2009</year>
<volume>30</volume>
<issue>6</issue>
<fpage>1127</fpage>
<lpage>1132</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuro.2009.06.009</pub-id>
<pub-id pub-id-type="pmid">19576930</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rocha</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sustained systemic Glucocerebrosidase inhibition induces brain alpha-Synuclein aggregation, microglia and complement C1q activation in mice</article-title>
<source/>Antioxid Redox Signal
          <year>2015</year>
<volume>23</volume>
<issue>6</issue>
<fpage>550</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2015.6307</pub-id>
<pub-id pub-id-type="pmid">26094487</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>HC</given-names>
</name>
</person-group>
<article-title>Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease</article-title>
<source/>Open Biol
          <year>2019</year>
<volume>9</volume>
<issue>1</issue>
<fpage>180177</fpage>
<pub-id pub-id-type="doi">10.1098/rsob.180177</pub-id>
<pub-id pub-id-type="pmid">30958120</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pacitti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Privolizzi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bax</surname>
<given-names>BE</given-names>
</name>
</person-group>
<article-title>Organs to cells and cells to organoids: The evolution of in vitro central nervous system modelling</article-title>
<source/>Front Cell Neurosci
          <year>2019</year>
<volume>13</volume>
<fpage>129</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2019.00129</pub-id>
<pub-id pub-id-type="pmid">31024259</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SEJH</given-names>
</name>
</person-group>
<article-title>Modeling ALS and FTD with iPSC-derived neurons</article-title>
<source/>Brain Res
          <year>2017</year>
<volume>1656</volume>
<fpage>88</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2015.10.003</pub-id>
<pub-id pub-id-type="pmid">26462653</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perriot</surname>
<given-names>SAM</given-names>
</name>
<name>
<surname>Perriard</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Canales</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jonkmans</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Merienne</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Meunier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>El Kassar</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Perrier</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Laplaud</surname>
<given-names>D-A</given-names>
</name>
<name>
<surname>Schluep</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Déglon</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Du Pasquier</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Human induced pluripotent stem cell-derived astrocytes are differentially activated by multiple Sclerosis-Associated Cytokines</article-title>
<source/>Stem Cell Reports
          <year>2018</year>
<volume>11</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2018.09.015</pub-id>
<pub-id pub-id-type="pmid">29996086</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lim</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>K-W</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Directly converted patient-specific induced neurons mirror the neuropathology of FUS with disrupted nuclear localization in amyotrophic lateral sclerosis</article-title>
<source/>Mol Neurodegener
          <year>2016</year>
<volume>11</volume>
<issue>1</issue>
<fpage>8</fpage>
<pub-id pub-id-type="doi">10.1186/s13024-016-0075-6</pub-id>
<pub-id pub-id-type="pmid">26795035</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKinney</surname>
<given-names>CE</given-names>
</name>
</person-group>
<article-title>Using induced pluripotent stem cells derived neurons to model brain diseases</article-title>
<source/>Neural Regen Res
          <year>2017</year>
<volume>12</volume>
<issue>7</issue>
<fpage>1062</fpage>
<lpage>1067</lpage>
<pub-id pub-id-type="doi">10.4103/1673-5374.211180</pub-id>
<pub-id pub-id-type="pmid">28852383</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aflaki</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Stubblefield</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Maniwang</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Moaven</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Goldin</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs</article-title>
<source/>Sci Transl Med
          <year>2014</year>
<volume>6</volume>
<issue>240</issue>
<fpage>240ra73</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3008659</pub-id>
<pub-id pub-id-type="pmid">24920659</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Awad</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Pannicker</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Deranieh</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Srikanth</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Peesay</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Zambidis</surname>
<given-names>ET</given-names>
</name>
<name>
<surname>Ricardo</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Feldman. Altered differentiation potential of Gaucher’s disease iPSC neuronal progenitors du to Wnt/Beta -catenin downregulation</article-title>
<source/>Stem Cell Reports
          <year>2017</year>
<volume>9</volume>
<fpage>1853</fpage>
<lpage>1867</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2017.10.029</pub-id>
<pub-id pub-id-type="pmid">29198828</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kouroupi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Taoufik</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vlachos</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Tsioras</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Antoniou</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Papastefanaki</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson’s disease</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2017</year>
<volume>114</volume>
<issue>18</issue>
<fpage>E3679</fpage>
<lpage>E3E88</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1617259114</pub-id>
<pub-id pub-id-type="pmid">28416701</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schondorf</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Aureli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McAllister</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Hindley</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis</article-title>
<source/>Nat Commun
          <year>2014</year>
<volume>5</volume>
<fpage>4028</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms5028</pub-id>
<pub-id pub-id-type="pmid">24905578</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Wade-Martins</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Commentary: Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models</article-title>
<source/>Front Neurosci
          <year>2016</year>
<volume>10</volume>
<fpage>578</fpage>
<pub-id pub-id-type="pmid">28066164</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Momcilovic</surname>
<given-names>ORS</given-names>
</name>
<name>
<surname>Oron</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mooney</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson’s Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<issue>5</issue>
<fpage>e0154890</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0154890</pub-id>
<pub-id pub-id-type="pmid">27191603</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brawner</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Generating CNS organoids from human induced pluripotent stem cells for modeling neurological disorders</article-title>
<source/>Int J Physiol Pathophysiol Pharmacol
          <year>2017</year>
<volume>9</volume>
<issue>3</issue>
<fpage>101</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="pmid">28694921</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitcairn</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wani</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Mazzulli</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson’s disease</article-title>
<source/>Neurobiol Dis
          <year>2019</year>
<volume>122</volume>
<fpage>72</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2018.03.008</pub-id>
<pub-id pub-id-type="pmid">29550539</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panicker</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Azevedo</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Awad</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2012</year>
<volume>109</volume>
<issue>44</issue>
<fpage>18054</fpage>
<lpage>18059</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1207889109</pub-id>
<pub-id pub-id-type="pmid">23071332</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monzio Compagnoni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kleiner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Samarani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aureli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Faustini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bellucci</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial dysregulation and impaired autophagy in iPSC-derived dopaminergic neurons of multiple system atrophy</article-title>
<source/>Stem Cell Reports
          <year>2018</year>
<volume>11</volume>
<issue>5</issue>
<fpage>1185</fpage>
<lpage>1198</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2018.09.007</pub-id>
<pub-id pub-id-type="pmid">30344007</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wren</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Atagi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>MD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells</article-title>
<source/>Mol Neurodegener
          <year>2015</year>
<volume>10</volume>
<fpage>46</fpage>
<pub-id pub-id-type="doi">10.1186/s13024-015-0042-7</pub-id>
<pub-id pub-id-type="pmid">26373282</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iovino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Agathou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>González-Rueda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Del Castillo</surname>
<given-names>V-HM</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Alberici</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations</article-title>
<source/>Brain
          <year>2015</year>
<volume>138</volume>
<fpage>3345</fpage>
<lpage>3359</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awv222</pub-id>
<pub-id pub-id-type="pmid">26220942</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallmann</surname>
<given-names>A-L</given-names>
</name>
<name>
<surname>Araúzo-Bravo</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Mavrommatis</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ehrlich</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Röpke</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brockhaus</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Astrocyte pathology in a human neural stem cell model of frontotemporal dementia caused by mutant TAU protein</article-title>
<source/>Sci Reports
          <year>2017</year>
<volume>7</volume>
<fpage>42991</fpage>
<pub-id pub-id-type="doi">10.1038/srep42991</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>di Domenico</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Calatayud</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pons-Espinal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Muñoz</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Richaud-Patin</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson's disease</article-title>
<source/>Stem Cell Reports
          <year>2019</year>
<volume>12</volume>
<issue>2</issue>
<fpage>213</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2018.12.011</pub-id>
<pub-id pub-id-type="pmid">30639209</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoes</surname>
<given-names>Martijn F.</given-names>
</name>
<name>
<surname>Bomer</surname>
<given-names>Nils</given-names>
</name>
<name>
<surname>van der Meer</surname>
<given-names>Peter</given-names>
</name>
</person-group>
<article-title>Concise Review: The Current State of Human In Vitro Cardiac Disease Modeling: A Focus on Gene Editing and Tissue Engineering</article-title>
<source/>STEM CELLS Translational Medicine
          <year>2018</year>
<volume>8</volume>
<issue>1</issue>
<fpage>66</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1002/sctm.18-0052</pub-id>
<pub-id pub-id-type="pmid">30302938</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DLaK</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>The use of brain organoids to investigate neural development and disease</article-title>
<source/>Nat Rev Neurosci
          <year>2017</year>
<volume>18</volume>
<issue>10</issue>
<fpage>573</fpage>
<lpage>584</lpage>
<pub-id pub-id-type="doi">10.1038/nrn.2017.107</pub-id>
<pub-id pub-id-type="pmid">28878372</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lancaster</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Renner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Wenzel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bicknell</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Hurles</surname>
<given-names>ME</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cerebral organoids model human brain development and microcephaly</article-title>
<source/>Nature
          <year>2013</year>
<volume>501</volume>
<issue>7467</issue>
<fpage>373</fpage>
<lpage>379</lpage>
<pub-id pub-id-type="doi">10.1038/nature12517</pub-id>
<pub-id pub-id-type="pmid">23995685</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sloan</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Darmanis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Birey</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Caneda</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human astrocyte maturation captured in 3D cerebral cortical spheroids derived from pluripotent stem cells</article-title>
<source/>Neuron
          <year>2017</year>
<volume>95</volume>
<issue>4</issue>
<fpage>779</fpage>
<lpage>790</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2017.07.035</pub-id>
<pub-id pub-id-type="pmid">28817799</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname>
<given-names>XNH</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ming</surname>
<given-names>GL</given-names>
</name>
</person-group>
<article-title>Using brain organoids to understand Zika virus-induced microcephaly</article-title>
<source/>Development
          <year>2017</year>
<volume>144</volume>
<issue>6</issue>
<fpage>952</fpage>
<lpage>957</lpage>
<pub-id pub-id-type="doi">10.1242/dev.140707</pub-id>
<pub-id pub-id-type="pmid">28292840</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bershteyn</surname>
<given-names>MNT</given-names>
</name>
<name>
<surname>Pollen</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Di Lullo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nene</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wynshaw-Boris</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kriegstein</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Human iPSC-derived cerebral organoids model cellular features of Lissencephaly and reveal prolonged mitosis of outer radial glia</article-title>
<source/>Cell Stem Cell
          <year>2017</year>
<volume>20</volume>
<issue>4</issue>
<fpage>435</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2016.12.007</pub-id>
<pub-id pub-id-type="pmid">28111201</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>PMR</given-names>
</name>
<name>
<surname>Pedrosa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kirschenbaum</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bayrak</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lachman</surname>
<given-names>HM</given-names>
</name>
</person-group>
<article-title>CRISPR/Cas9-mediated heterozygous knockout of the autism gene CHD8 and characterization of its transcriptional networks in cerebral organoids derived from iPS cells</article-title>
<source/>Mol Autism
          <year>2017</year>
<volume>8</volume>
<fpage>11</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-017-0124-1</pub-id>
<pub-id pub-id-type="pmid">28321286</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deyle</surname>
<given-names>DRRD</given-names>
</name>
</person-group>
<article-title>Adeno-associated virus vector integration</article-title>
<source/>Curr Opin Mol Ther
          <year>2009</year>
<volume>11</volume>
<issue>4</issue>
<fpage>442</fpage>
<lpage>447</lpage>
<pub-id pub-id-type="pmid">19649989</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daya</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Berns</surname>
<given-names>KI</given-names>
</name>
</person-group>
<article-title>Gene therapy using adeno-associated virus vectors</article-title>
<source/>Clin Microbiol Rev
          <year>2008</year>
<volume>21</volume>
<issue>4</issue>
<fpage>583</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1128/CMR.00008-08</pub-id>
<pub-id pub-id-type="pmid">18854481</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sardi</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kinnecom</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tamsett</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stanek</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Passini</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Grabowski</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Schlossmacher</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Sidman</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>SH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2011</year>
<volume>108</volume>
<issue>29</issue>
<fpage>12101</fpage>
<lpage>12106</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1108197108</pub-id>
<pub-id pub-id-type="pmid">21730160</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massaro</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mattar</surname>
<given-names>CNZ</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>AMS</given-names>
</name>
<name>
<surname>Sirka</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>SMK</given-names>
</name>
<name>
<surname>Herbert</surname>
<given-names>BR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fetal gene therapy for neurodegenerative disease of infants</article-title>
<source/>Nat Med
          <year>2018</year>
<volume>24</volume>
<issue>9</issue>
<fpage>1317</fpage>
<lpage>1323</lpage>
<pub-id pub-id-type="doi">10.1038/s41591-018-0106-7</pub-id>
<pub-id pub-id-type="pmid">30013199</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marshall</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McEachern</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Kyros</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Nietupski</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Budzinski</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>RJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model</article-title>
<source/>Mol Ther
          <year>2002</year>
<volume>6</volume>
<issue>2</issue>
<fpage>179</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="doi">10.1006/mthe.2002.0650</pub-id>
<pub-id pub-id-type="pmid">12161184</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sardi</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Viel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tamsett</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Treleaven</surname>
<given-names>CM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2013</year>
<volume>110</volume>
<issue>9</issue>
<fpage>3537</fpage>
<lpage>3542</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1220464110</pub-id>
<pub-id pub-id-type="pmid">23297226</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de la Mata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cotan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Oropesa-Avila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Garrido-Maraver</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cordero</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Villanueva Paz</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacological chaperones and coenzyme Q10 treatment improves mutant beta-Glucocerebrosidase activity and mitochondrial function in Neuronopathic forms of Gaucher disease</article-title>
<source/>Sci Rep
          <year>2015</year>
<volume>5</volume>
<fpage>10903</fpage>
<pub-id pub-id-type="doi">10.1038/srep10903</pub-id>
<pub-id pub-id-type="pmid">26045184</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fog</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Zago</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Malini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Solanko</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Peruzzo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bornaes</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase</article-title>
<source/>EBioMedicine
          <year>2018</year>
<volume>38</volume>
<fpage>142</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1016/j.ebiom.2018.11.037</pub-id>
<pub-id pub-id-type="pmid">30497978</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maegawa</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Tropak</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Buttner</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Rigat</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Fuller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pandit</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease</article-title>
<source/>J Biol Chem
          <year>2009</year>
<volume>284</volume>
<issue>35</issue>
<fpage>23502</fpage>
<lpage>23516</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M109.012393</pub-id>
<pub-id pub-id-type="pmid">19578116</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parenti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Andria</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Valenzano</surname>
<given-names>KJ</given-names>
</name>
</person-group>
<article-title>Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders</article-title>
<source/>Mol Ther
          <year>2015</year>
<volume>23</volume>
<issue>7</issue>
<fpage>1138</fpage>
<lpage>1148</lpage>
<pub-id pub-id-type="doi">10.1038/mt.2015.62</pub-id>
<pub-id pub-id-type="pmid">25881001</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Migdalska-Richards</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Daly</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bezard</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schapira</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice</article-title>
<source/>Ann Neurol
          <year>2016</year>
<volume>80</volume>
<issue>5</issue>
<fpage>766</fpage>
<lpage>775</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24790</pub-id>
<pub-id pub-id-type="pmid">27859541</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aflaki</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Borger</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Moaven</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Stubblefield</surname>
<given-names>XBK</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Patnaik</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schoenen</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Westbroek</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sidhu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Khaliq</surname>
<given-names>ZM</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Ory</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Marugan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>A New Glucocerebrosidase Chaperone Reduces -Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism</article-title>
<source/>J Neurosci
          <year>2016</year>
<volume>36</volume>
<issue>28</issue>
<fpage>7441</fpage>
<lpage>7452</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0636-16.2016</pub-id>
<pub-id pub-id-type="pmid">27413154</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazzulli</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Zunke</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tsunemi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Toker</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Burbulla</surname>
<given-names>LF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of beta-Glucocerebrosidase reduces pathological alpha-Synuclein and restores lysosomal function in Parkinson's patient midbrain neurons</article-title>
<source/>J Neurosci
          <year>2016</year>
<volume>36</volume>
<issue>29</issue>
<fpage>7693</fpage>
<lpage>7706</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0628-16.2016</pub-id>
<pub-id pub-id-type="pmid">27445146</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khanna</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Pellegrino</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schilling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rigat</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Soska</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase</article-title>
<source/>FEBS J
          <year>2010</year>
<volume>277</volume>
<issue>7</issue>
<fpage>1618</fpage>
<lpage>1638</lpage>
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2010.07588.x</pub-id>
<pub-id pub-id-type="pmid">20148966</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hemmelgarn</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Melrose</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Hein</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fuller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease</article-title>
<source/>Blood Cells Mol Dis
          <year>2013</year>
<volume>51</volume>
<issue>2</issue>
<fpage>109</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcmd.2013.03.006</pub-id>
<pub-id pub-id-type="pmid">23642305</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawkar</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>D'Haeze</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease</article-title>
<source/>Cell Mol Life Sci
          <year>2006</year>
<volume>63</volume>
<issue>10</issue>
<fpage>1179</fpage>
<lpage>1192</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-005-5437-0</pub-id>
<pub-id pub-id-type="pmid">16568247</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rahimpoura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lua</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pacakb</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ikejiria</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones</article-title>
<source/>PNAS
          <year>2013</year>
<volume>110</volume>
<issue>3</issue>
<fpage>966</fpage>
<lpage>971</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1221046110</pub-id>
<pub-id pub-id-type="pmid">23277556</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xi Lu</surname>
<given-names>YD</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lui</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Histone acetyltransferase p300 mediates histone acetylation of PS1 and BACE1 in a cellular model of Alzheimer’s disease</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>7</issue>
<fpage>e103067</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0103067</pub-id>
<pub-id pub-id-type="pmid">25051175</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S-Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X-H</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>C-M</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>ZY</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X-D</given-names>
</name>
</person-group>
<article-title>FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70</article-title>
<source/>Biochem Biophys Res Commun
          <year>2007</year>
<volume>356</volume>
<fpage>998</fpage>
<lpage>1003</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2007.03.076</pub-id>
<pub-id pub-id-type="pmid">17397803</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yanga</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chena</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yea</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Lonsera</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Zhuanga</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease</article-title>
<source/>PNAS
          <year>2011</year>
<volume>108</volume>
<issue>52</issue>
<fpage>21200</fpage>
<lpage>21205</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1119181109</pub-id>
<pub-id pub-id-type="pmid">22160715</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munkacs</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>Brinkman</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Higaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gutiérrez</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Chaudhar</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Layer</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boone</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ioannou</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Sturley</surname>
<given-names>SL</given-names>
</name>
</person-group>
<article-title>An “Exacerbate-reverse” Strategy in Yeast Identifies Histone Deacetylase Inhibition as a Correction for Cholesterol and Sphingolipid Transport Defects in Human Niemann-Pick Type C Disease</article-title>
<source/>J Biol Chem
          <year>2011</year>
<volume>286</volume>
<issue>27</issue>
<fpage>23842</fpage>
<lpage>23851</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.227645</pub-id>
<pub-id pub-id-type="pmid">21489983</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pipaliaa</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Cosnerb</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Huanga</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chatterjeeb</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bourbonb</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Farleyb</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Helquistb</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wiestb</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Maxfielda</surname>
<given-names>FR</given-names>
</name>
</person-group>
<article-title>Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts</article-title>
<source/>PNAS
          <year>2011</year>
<volume>108</volume>
<issue>14</issue>
<fpage>5620</fpage>
<lpage>5625</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1014890108</pub-id>
<pub-id pub-id-type="pmid">21436030</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>